

DOCKET NO.: UPAP0025-100

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

JAN 22 2004

OFFICIAL

In re patent application of: David B. Weiner *et al.*

Serial No.: 09/719,067

Group No.: 1632

Filing Date: August 16, 2001

Examiner: Ram Shukla

For: METHODS AND COMPOSITIONS FOR DELIVERING PROTEINS TO
MACROPHAGE CELLS AND CELLS OF MACROPHAGE DERIVED
LINEAGES

DECLARATION OF DR. DAVID B. WEINER
PURSUANT TO 37 CFR § 1.132

I, Dr. David B. Weiner, declare as follows:

1. I am an inventor in the above-identified patent application.
2. Attached hereto are Exhibits 2-4 that indicate the level of skill and knowledge of those in the art at the time the above-identified application was filed. The exhibits demonstrate that at the time the invention was made, the drainage patterns associated with parts of the lymphatic system were reasonably well understood and reasonably predictable. The exhibits demonstrate that at the time the invention was made, one having ordinary skill in the art could determine the drainage pattern(s) of the lymphatic system and correlate a site of injection to a particular lymph node using routine methodology without undue experimentation.
3. Exhibit 2 states that "For ... the arms or legs, the lymphatic drainage patterns are fairly predictable: the arm drains to the axilla, and the leg drains to the groin." (Exhibit 2, Oncolog, taken from www3.mdanderson.org/~oncolog/map.html, page 1). Exhibit 2 further states, "When the drainage patterns are ambiguous, lymphoscintigraphy is used to identify nodal

DOCKET NO.: UPAP0025-100
PATENT

SERIAL NO.: 09/719,067
FILED: August 16, 2001

basins...Lymphoscintigraphy begins with injection of a radiolabeled colloid into the skin...Over the course of a few minutes, the colloid passes through the dermal lymphatics to one or more lymph node basins, where it is taken up by the macrophages in the lymph nodes. A scintillation camera is then used to document the path of the radiolabeled colloid through the lymphatic system." (Exhibit 2, page 2,).

4. Exhibit 3 describes in more detail the method of finding lymph nodes using lymphoscintigraphy. As described on page 1 of Exhibit 3 (taken from www.nucmednet.com/lymph.htm, entitled "Procedure of the Month November 1997), "since one of the functions of the lymph system is to clear small particles, the ...particles injected during lymphoscintigraphy go to the local lymph nodes. Since these particles have a radioactive label, we can find them using nuclear medicine equipment."

5. Exhibit 4 (Eddy et al. World J. Surg. (2001) 25:794-797) describes lymphoscintigraphy and lymphatic mapping for identification for sentinel lymph nodes. In describing the technique the authors state "investigators obtain a lymphoscintigram to delineate lymphatic drainage." (Eddy, p. 796, left column).

6. These references demonstrate that at the time the invention was made one of skill in the art could identify the site of administration required to deliver a DNA molecule to a specific lymph node based upon the lymphatic drainage system that was either known or that was determined using techniques that would not require undue experimentation.

7. I declare that statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: 1/07/04

By: 

Dr. David B. Weiner

DOCKET NO.: UPAP0025-100
PATENT

SERIAL NO.: 09/719,067
FILED: August 16, 2001

Exhibit 1: Curriculum vitae of Dr. David B. Weiner

Exhibit 2: Oncolog: Intraoperative Lymphatic Mapping—Elegant Way to Identify Lymph
Node Metastases in Melanoma Patients taken from
www3.madanderson.org/~oncolog/map.html

Exhibit 3: "NucMedNet Feature Procedure: New Techniques for Finding Lymphnodes in
Cancer Patients" taken from www.nucmednet.com/lymph.htm.

Exhibit 4: Eddy et al. World J. Surg. (2001) 25:794-797

**DOCKET NO.: UPAP0025-100
PATENT**

**SERIAL NO.:09/719,067
FILED: AUGUST 16, 2001**

**EXHIBIT 1 FOR DECLARATION OF
DR. DAVID B. WEINER**

CURRICULUM VITAE

DAVID B. WEINER, Ph.D.

Office Address:

University of Pennsylvania
505A Stellar Chance Laboratories
422 Curie Drive
Philadelphia, PA 19104
(215) 349-8365 (215)-573-9436 (Fax)

Education:

1974-1978 B.S. SUNY at Stony Brook, NY (Biology)
1981-1985 M.S. University of Cincinnati, Cincinnati, OH, (Biology)
1981-1986 Ph.D. University of Cincinnati, Cincinnati, OH,
Developmental Biology Graduate Program, College of Medicine

Postgraduate Training and Fellowship Appointments:

12/1/86-6/30/88 Immunology Research Fellow: Division Director, Mark I. Greene, M.D., Ph.D., Department
of Pathology and Laboratory Medicine University of Pennsylvania

Faculty Appointments:

7/1/88 Research Associate of Pathology and Laboratory Medicine,
University of Pennsylvania School of Medicine, Philadelphia, PA.
7/1/89 Research Assistant Professor of Medicine,
University of Pennsylvania School of Medicine, Philadelphia, PA.
9/1/89 Wistar Institute, Assistant Professor,
University of Pennsylvania School of Medicine, Philadelphia, PA.
7/1/90 Wistar Institute Assistant Professor of Medicine (secondary),
University of Pennsylvania School of Medicine, Philadelphia, PA.
7/1/93 Assistant Professor of Pathology and Laboratory Medicine,
University of Pennsylvania School of Medicine, Philadelphia, PA.
7/1/95 Associate Professor of Pathology and Laboratory Medicine,
University of Pennsylvania School of Medicine, Philadelphia, PA.
9/1/98 Associate Professor of Pathology and Lab Medicine
Adjunct in Otorhinolaryngology: Head and Neck Surgery.
University of Pennsylvania School of Medicine, Philadelphia, PA.

Hospital and Administrative Appointments:

1990-1993 Director of Biotechnology, Wistar Institute, Philadelphia PA
1996-2000 Chair, AIDS and Infectious Diseases Research Program, Institute for Human Gene Therapy
2003 Member-University of Pennsylvania CFAR Executive Committee
2003-present Member Pathology & Laboratory Medicine Roundtable

Awards, Honors, and Memberships in Honorary Societies:

1973-1978 Regents Scholarship Award
 1974 Bay Ridge Medical Society Award for Excellence in Science
 1976-1977 Lupus Foundation of Greater New York Biomedical Research Awards
 1982 Lions Club Service Award
 1982-1983 Graduate Research Fellowship - Academic Year
 1983 Weinman Summer Fellowship
 1983-1984 Graduate Research Fellowship - Academic Year
 1984 URC Summer Fellowship
 1984 Sigma Xi Research Fellowship
 1984-1985 President Biomedical Graduate Student Association.
 1985 Sigma Xi Young Investigator Award
 1985 URC Summer Fellowship
 1991 1991 Rose Award Sponsor
 1993 Rose Award Sponsor
 1993 Philadelphia Business Award top 100 Philadelphian's of 1993
 1994 WHO AIDS Research Laboratory Advisory Meeting
 1995 The B.F. Goodrich Collegiate Inventors Program-Honorable mention
 1997 The John Morgan Society
 1998 Nobel Symposium on DNA Vaccines, Stockholm
 1998 Pfizer Traveling Fellow
 1999 US Department of Health and Human Services, Public Health Services NIH Recognition Award
 2000 Outside Thesis Opponent - Karolinska Institute, Stockholm
 2001 ICAAC-ASM-Program Committee Award- Outstanding study in Microbial Pathogenesis
 2001 Nobel Symposium on HIV Vaccines, Stockholm
 2002 Outside Thesis Opponent - Karolinska Institute, Stockholm

Membership in Professional Societies:

*American Association for the Advancement of Science
 *International AIDS Society
 *American Society for Microbiology
 *Clinical Immunology Society
 *FASEB-American Association of Immunology
 *Greater Philadelphia Economic Development Council
 *Pennsylvania Biotechnology Association
 *Ben Franklin Technology Council
 *International Working Group on the Standardization and Control of Nucleic Acid Vaccines

Service Positions:

-Senior Editor, DNA and Cell Biology
 -Section Editor, Viral Immunology
 -Editorial Board, Immunologic Research
 -Editorial Board, Gene Vaccines & Therapy
 -Pennsylvania Biotechnology Association
 -Pennsylvania Bar Association- Special Section on Biomedical issues (1997)
 -Special Consultant-NY City Dept of Consumer Affairs, AIDS Fraud Division (1994-1999)
 -Gordon Conferences: Chair, Genetic Vaccines (1998).
 -Special Consultant-FDA-CEBR-Biologics (1995-present)
 -NIAID/NIH-Study Section-NCVDG Ad Hoc -1993, 1994, 1995, 1997.

- NIAID/NIH Study Section -Ad Hoc-1994, 1995, 1997, 1998, 1999.
- NIH Inter Institute Program review for the Development of HIV related Therapeutics 2002
- NIAID/NIH study Section permanent Member AAR4 (1994-2001) Ad Hoc 2003
- WHO Special Advisor Genetic Vaccines 1993, 1995, 1998
- WHO/NIBSC Special Advisor – Safety of Molecular Adjuvants and DNA Vaccine technology 1999
- WHO Advisory Panel 2000- Issues for Implementation of HIV Vaccines in Developing Nations.
- WHO Advisory Panel 2000-Safety Issues facing DNA vaccines
- Faculty Review Panel - Institute Pasteur,
- Advisory Board for the National Center for Study of Aging in Chimpanzees (1997-2000)
- Guest Editor-Your World, Biotechnology and You 2000
- National Institute of Biological Standards and Control (European FDA Advisory Board Member) – Genetic Vaccines & Therapeutics, 1997-Present
- Galaxo Smith Klein – GSK/SK – PEARL Advisory Panel Member (1997-2003)
- Special Advisor American Home Products – Vaccines (1998-Present)
- U.S. civilian Research & Development Foundation(CDRF) Review Committee 2001, 2002, 2003
- EPIVAX- Advisory Board 1999-Present
- Global Alliance to Immunize Against Aids- GAIA- Advisory Board- 2001-Present
- Advisory Board - RIGHT (2000-2004)
- Scientific Review FWF-Austrian Science Fund (2001, 2002, 2003)
- Faculty Promotion Review Committee- Institute Pasteur, Paris 2001
- Department of Veterans Affairs- Merit Review Subcommittee for Infectious Diseases (2001-Present)
- Board Member CANVAC (Canadian Vaccine for Aids Council) –2001-Present
- NIAID/NIH-Study Section - HIV Vaccine Design and Development Team Review Panel 2002 & 2003
- PBS television and webcast-NOVA-Advisory consultant - Bioterrorism - Nov 2002
- Faculty Promotion Review Committee- University of London, England 2002
- Advisory Board Review Panel - Elan Pharmaceuticals – 2002
- Oregon Public Television Series on gene Therapy Episode #8 Building DNA vaccines (David Weiner) 2002
- Advisory Board-European Commission for an AIDS VACCINE INTEGRATED PROJECT (AVIP)
- AACTG- Immunology RAC (I-RAC) – 2003
- HIV Experimental Vaccine Directory Review – AmFar –2003
- Forum For Collaborative HIV Research - Therapeutic Vaccines: Moving The Field Forward - Panel Member- 2003
- The Welcome Trust – International Senior Research Fellowship in Biomedical Science - Reviewer – 2003.
- NIAID/NIH Study Section- CFAR Special Emphasis review panel- 2003.
- NIAID/NIH Study Section-Special Emphasis review panel- loan repayment program- 2003.
- NIAID/NIH Study Section- Special Emphasis review Panel- ZRG1Microbials Immunology-2003
- AAAS Research Competitiveness Service- Faculty Grant Competition Review Panel- 2004.

Training and Major Teaching and Clinical Responsibilities for the University of Pennsylvania,

Course Teaching:

Division of Rheumatology	1989 - 1999	Fellows Training lecture in Molecular Biology
Department of Otolaryngology	1992- 2000	Fellows Training lecture in Immunology
Rheumatology Bridge	1993-2000	molecular biology/ immunology Section

Medical School Immunology Course Director 1997, 1998,
 Medical School Immunology Course Instructor 1995, 1999, 2000, 2001, 2002
 Graduate School Course in Gene Therapy – Instructor 1996 - Present
 Medical School Frontiers in HIV course – Instructor 1999 - Present
 Bioengineering – Biotechnology Course – Instructor 1999 - Present
 Immunology 999 – Instructor 1999-Present

Microbiology 520 - Instructor 2000-Present
Frontiers in HIV Medicine - lecturer 2000-present
Abramson Cancer Center University of Pennsylvania Post Graduate Program - Current Aspects in the Diagnosis and Treatment of Prostate Cancer - Immune Therapy for Prostate Cancer - 2003.
Course Director - Vaccination and Immune therapy - 2003
Member - U. Pennsylvania - Graduate Group in Immunology 1992 - present
Member - U. Pennsylvania - Graduate Group in Pharmacology 1993 - present
Member - U. Pennsylvania - Graduate Group in Cell and Molecular Biology 1996 - present
CFAR- Developmental Core Pilot Project Grant Review 2003.
Emerging Infectious Diseases- 2003- Lecturer
Pharmacology Graduate Lecturer 590 - 2000- 2004.

Academic Committees at the University of Pennsylvania:

1989 Graduate Faculty, Immunology Program, University of Pennsylvania, Philadelphia, PA
1990 Graduate Faculty, Pharmacology Program, University of Pennsylvania, Philadelphia, PA
1993 COAP - Clinician Educator Track - Dept. of Pathology and Lab Medicine, University of Pennsylvania, Philadelphia, PA
1998 Graduate Faculty in Cell and Molecular Biology, University of Pennsylvania, Philadelphia, PA
1995 - Present,
Admissions interviewer for CAMB Graduate Program
Immunology Graduate Program
CAMB Graduate Program
Pharmacology Graduate Program
MD/Ph.D. Candidate interviewer
Medical School Admission interviewer
2003 CFAR- Developmental Core Pilot Project Grant Review
2003 CFAR Executive Committee Member

Parents:

5,338,829 Peptides derived from human immunodeficiency virus-1 GP160

6,667,157 Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus VPR protein

5,763,190 Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocorticoid receptor type II and viral protein R interacting protein

6,468,982 Genetic immunization

6,348,449 Methods of inducing mucosal immunity

6,197,755 Compositions and methods for delivery of genetic material

5,981,505 Compositions and methods for delivery of genetic material

5,962,428 Compositions and methods for delivery of genetic material

5,830,876 Genetic immunization

- 5,817,637 Genetic immunization
- 5,739,118 Compositions and methods for delivery of genetic material
- 5,593,972 Genetic immunization
- 5,780,238 VPR receptor protein
- 5,714,316 Chimeric envelope proteins for viral targeting
- 5,874,225 Identification of compounds that modulate HIV-1 vpr protein activity
- 5,780,220 Methods and compositions for inhibiting HIV replication

Selected Lectures (1993 -Present):

- 1993 Conference Co-Organizer-Bioeast 1993. January
- 1993 Chair-Genetic Vaccination -Genetic Vaccine development, a new approach to developing protective anti-HIV immune responses-Bioeast, Washington DC. January.
- 1993 HIV-cell Interactions and Anti-HIV Immune Responses, La Jolla Institute for Allergy and Immunology, La Jolla, CA. March.
- 1993 HIV Genes, Viral Tropism and Cell Entry, DNX, Princeton, N.J. March.
- 1993 An anti-oncogene is encoded in the HIV genome, Interplex, NYC. March.
- 1993 Chair: Genetic Vaccination Implications of the Technology, Atlanta ASM. May
- 1993 Chair: HIV Regulatory Genes and HIV Pathogenesis, Atlanta ASM. May
- 1993 Genetic Vaccination Induces Protective anti-HIV Immune Responses In Vivo. NJ. IGI. June
- 1993 Genetic Vaccination against HIV-1. Washington DC, NIAID-DAIDS-NCDDG. July.
- 1993 Vpr Induction of Cell Differentiation. Washington, DC, NIAID-DAIDS-NCDDG. July.
- 1993 Induction of Humoral and Cellular anti-HIV Immune Responses Through Genetic Inoculation. Boston - Science Annual Meeting on New Technologies. August.
- 1993 Pathogenesis of HIV Infection is controlled by a Regulatory Gene. CUNY Dept. Microbiology New York, September.
- 1993 Cloning and biological characterization of Single chain Fv fragments that mediate Neutralization of HIV-1 *in vitro*. Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor, NY. September.
- 1993 Genetic Inoculation Induces CTL Responses against HIV. International Biotechnology Conference. Washington, D.C. October.
- 1993 Vaccination against Human Retroviruses using Plasmid Vectors, ICAAC Symposium. New Orleans. October.
- 1993 Infectivity and Pathogenesis of HIV. Immune Response Institute. Princeton, N.J., October
- 1993 Induction of Protective Immunity against HIV-1 by Genetic Inoculation. International European AIDS EVA conference. Munich, Germany. November.
- 1993 Human Retroviruses-vpr and HIV-1 Pathogenesis. NIH, National Institutes of Health/NCVDG. December.
- 1994 Facilitated DNA Inoculation Induces Cellular and Humoral Immunity against HIV-1. UCLA Meeting on AIDS. Hilton Head. S. Carolina. January.
- 1994 Induction of Immune Responses Through Direct Genetic Inoculation. First International Conference on Gene Therapy & Vaccines for Cancer (BioEast 94). January.

- 1994 Safety concerns : Utilizing Facilitated DNA Inoculation for the Production of In Vivo Immune Responses. NIAID 1PHS AIDS Vaccine Research and Development Subgroup Meeting. Rockville, MD. February.
- 1994 DNA Immunization for the Induction of in vivo immunity. Walter Reed Ground Rounds in Infectious diseases. February.
- 1994 Gene Inoculation as a tool to develop Protective Immune Responses In Vivo. Chair. Vaccines New Technology & Applications. CHI. Alexandria, VA. March
- 1994 Genetic Inoculation Induces Broad Immunity Against HIV-1. 9th Annual Conference on Clinical Immunology. Anaheim California. April.
- 1994 Facilitated DNA Inoculation for the Generation of Antiviral Immune Responses in vivo. Insitut fur Medizinische Virologie der University of Zurich. Switzerland. May.
- 1994 DNA Inoculation As a putative HIV Vaccine, 1st International Meeting on DNA Vaccination Technology . The World Health Organization, Geneva, Switzerland. May
- 1994 Gene inoculation Induces Protective Immune Responses. NCI-FCRDC, Fredrick, Maryland. May.
- 1994 Anti-HIV -1 Approaches Based on an HIV-1 Regulatory Gene. Maryland Medical Labs. Bethesda, Maryland. June.
- 1994 Nucleic Acid Inoculation for the Generation of Protective Immune Responses and as a Novel Approach to Gene Therapy. Molecular Genetics and Protein Chemistry Seminar. Pfizer Inc, Groton, Conn. June.
- 1994 Nucleic Acid Vaccines for the Control of HIV-1 Infection. U.S. Naval Hospital, Bethesda, MD. Molecular Biology Series. July 1994.
- 1994 Immune Based Therapies For Human Retroviral Infections International Symposium on Cytokines and Immunology Oxford, England, September
- 1994 CHAIR, HIV Accessory Genes, Annual Laboratory for Tumor Cell Biology meeting. Rockville, M.D. September.
- 1994 The Role of vpr in HIV-1 Infection and Latency. Annual Laboratory for Tumor Cell Biology Meeting. Rockville, MD. September
- 1994 CHAIR: Gene Therapy Approaches to HIV-1 Annual Laboratory for Tumor Cell Biology . Rockville MD. October.
- 1994 Facilitated in vivo DNA Inoculation Generates Expression and Immunogenicity in vivo. Technological Advances for Gene Therapy. Washington, D.C. November.
- 1994 CHAIR: Facilitated DNA Inoculation Produces Specific Gene Expression In Vivo which Induces Specific Immune Responses in the Absence of Replicating Vector Systems. IBC Fourth Conference on Gene Therapy. Washington, DC. November.
- 1994 DNA Inoculation can Induce Protective Immunity in Nonhuman Primates: Advances in Gene Therapy. CHI, Washington, D.C. December.
- 1995 Conference organizer & Chair DNA Inoculation Induces Broad Anti-HIV Immunity In Vivo. Gene Therapy & Nucleic Acid Vaccine Strategies. Bethesda, MD. February
- 1995 Chair, Direct DNA Immunization for the Production of Anti-HIV Immune Responses in vivo Second International Conference on Engineered Vaccines for Cancer and AIDS. San Francisco, California. March.
- 1995 Results with Genetic Immunization. Third Annual Conference on Vaccines: New Technologies & Applications. Alexandria, VA. March.
- 1995 Nucleic Acid Vaccination : Studies in the HIV-1 Model. Southwestern Medical Center. U of Texas at Dallas. May.
- 1995 DNA Vaccines for HIV-1; Progress Toward Vaccine Development Fourth Annual NCDDG/SPIRAT Meeting/DAIDS/NAIAD, Bethesda MD. July.
- 1995 Co Chair, HIV Accessory Genes: The role of viral Protein R (vpr) in HIV-1 Pathogenesis, Annual Meeting Laboratory for Tumor Cell Biology. Rockville, M.D. September.

- 1995 Genetic Immunotherapy for HIV-1, Efficacy in Non Human Primates. Annual Laboratory for Tumor Cell Biology Meeting. Rockville, MD. September.
- 1995 Development of DNA Vaccines for Clinical Applications. University of Alabama Birmingham Center for Gene Therapy. September
- 1995 Immune Responses to HIV-1 Developed by DNA Inoculation. Overview and Status of HIV: Conference on Disease, Prevention and Control- Pavia, Italy. October.
- 1995 Vpr and HIV-1 pathogenesis and protective immune responses. Department of Microbiology, University of Mass. October.
- 1995 Development of Effective Human DNA Vaccines. Walter Reed Army Medical Center. November.
- 1995 The Challenge of Vaccine Development for HIV, European Vaccines Meeting- Institute Pasteur, Paris, France. November.
- 1995 Immune Receptors and Molecular Engineering of Immune Responses. 3M Company, Minnesota. December.
- 1996 Rational Vaccine Design for HIV, BIOEAST Conference, Washington D.C. January
- 1996 Vpr Controls HIV Replication in Host Cells. International Conference on Human Retroviruses. ASM. Washington, D.C. January.
- 1996 Engineering Multicomponent DNA Vaccines. WHO Conference on Genetic Immunization. Washington, D.C. February.
- 1996 Immune Responses in Non-human primates induced through cDNA Vaccine for HIV-1. WHO Conference. Washington, D.C. February.
- 1996 Designing safe effective DNA Vaccines-FDA meeting on safety of Genetic Vaccines. Washington, D.C. February
- 1996 Protective immune response to HIV by DNA vaccination, IBC Conference, Alexandria, VA. February.
- 1996 Corruption of Host Cells by HIV-1 vpr. University of South Florida Medical Center, Tampa, FL. April.
- 1996 Development of Human Retroviral Vaccines. Elsevier Science Publishers Lectureship. 12th Annual Clinical Virology Symposium. Clear water Beach, FL. April
- 1996 DNA Vaccine Design for HIV-1: Combination Antigen Expression Cassettes and Molecular Adjuvant Generate Effective Anti-viral Immunity in Vivo. Genes that Induce Immunity Symposium. Karlinska Institute. Stockholm, Sweden. May.
- 1996 The Scientific Future of Genetic Immunization. American Society for Microbiology. Aruba. May
- 1996 Scientific Basis and Potential for DNA Vaccines. Lederlie WLVP Research Meeting. Cooperstown, NY. June
- 1996 HIV-1 vpr Regulates the state of the Host IARCA International Meeting, Paris, France. June.
- 1996 From Mouse to Man: DNA Vaccination as a vaccine/immune therapeutic approach for HIV-1. Trinity College, Oxford, England. Sept.
- 1996 HIV-1 vpr as a Positive Regulator of Viral Production through Targeted Cellular Dysfunction". Workshop on HIV and Cells of the Macrophage Lineage. Verenna, Lake Como, Italy. October
- 1996 Genetic Immunization-DNA Vaccines. New Insights in HIV Infection and Disease: 3rd Inter. Conf. on Engineered Vaccines for Cancer and AIDS. Hilton Head, South Carolina. October
- 1996 From Mouse to man: DNA Vaccination for HIV-1. Genetic Immunization, Chairman, IBC USA Conferences. Washington D.C. October.
- 1996 Gene immunotherapy for HIV-1. Project Inform. Atlanta, GA 1996. October
- 1996 Engineering Vaccines in the 1990's. Thomas Jefferson University. Philadelphia, PA. November
- 1996 Protection in Primates from HIV-1 by DNA vaccination. Dept. of Pathology Seminar Series. NYU. November
- 1996 HIV-1 vpr as a Target for Drug development. GHI. Novel HIV Therapeutic Strategies. Washington D.C. November
- 1996 Engineering Genes as Vaccines for newly emerging pathogens. Rabies and Viral Vaccines Conference. CDC. Washington D.C. December

- 1997 Clinical Responses from DNA Vaccines. Technologies for the 21st Century. ZIA Symposium. New Mexico. January
- 1997 Engineering DNA Vaccines for HIV-1. Current Aspects of Vaccinology and Molecular Virology. Drug Information Associates. Dana Point, CA. April
- 1997 DNA Vaccines for HIV-1. HIV Vaccine for Developing Countries. Harvard AIDS Institute. Devon, MA. April
- 1997 Engineering DNA Vaccines for HIV-1. Harvard AIDS Seminar Series. Harvard AIDS Institute. Boston, MA. April
- 1997 Immune Responses to DNA Vaccines. Preclinical and Clinical Development of the New Vaccines. Institut Pasteur. Paris, France. May
- 1997 Developing DNA Vaccines for Clinical use what we have learned from the first studies. Proposed International Working Group on the Standardization and Control of DNA Vaccines. National Institute for Biological Standards and Control. May
- 1997 Novel HIV Therapies: from discovery to clinical proof-of-concept. NIAID, SPIRAT/NCDDG-HIV program. Gathersburg, MD. June.
- 1997 New Opportunities for HIV Therapy: Clinical Update. NIAID, SPIRAT/NCDDG-HIV program. Vienna, VA. June.
- 1997 Primate Models Generated by Mammalian Cloning. BioConferences International Inc.: Mammalian Cloning: Implications for Science and Society. Washington D.C. June.
- 1997 Immunological Approaches and Considerations For Antiviral Therapy. Hepatitis B Foundations, 3rd Annual Princeton Workshop. Princeton, NJ. September.
- 1997 Engineering Improved DNA Vaccines for HIV1. 5th International Workshop on Tolerance and Immune Regulation. September.
- 1997 Animal Models Session. Second Annual Meeting of the Institute of Human Virology. Baltimore, MD. September.
- 1997 DNA AIDS Vaccines: Of Mice and Humans. Society of Toxicology, Fall Scientific Meeting. Philadelphia, PA. November.
- 1997 (gene therapy) Therapeutic Immunology Subcommittee of the ACTG Immunology Research Agenda Committee. Arlington, VA. December.
- 1998 T-Cells as Reservoirs for HIV Under HAART: Therapeutic Options and biological Requirements. Cellular and Systemic Reservoirs for HIV Replication Under Highly Active Antiretroviral Therapy. Dedham, MA. February.
- 1998 Engineering DNA Vaccines for HIV-2. National Cancer Institute. Bethesda, Maryland. February.
- 1998 Acquired immune deficiency syndrome (AIDS): DNA vaccines. Advanced Seminar in Gene Therapy. Philadelphia, PA. Spring.
- 1998 Gene Therapy. AAAS Symposium. Philadelphia, PA. February.
- 1998 Multicomponent DNA Vaccines for HIV. National Immunology Investigators Meeting. Bodega Bay, CA
- 1998 Assembly of Multicomponent DNA Vaccines. Gene Therapy Seminar Series. Ann Arbor, Michigan. May .
- 1998 Analysis of Multicomponent DNA Vaccines for HIV-1. DAIDS Workshop on Primate Evaluations of AIDS Vaccines (NIH). Bethesda, Maryland, May.
- 1998 Building DNA Gene Vaccines for HIV. The American Society of Gene Therapy, 1st Annual Meeting. Seattle, Washington. May.
- 1999 Next Generation DNA Vaccines: the HIV Model. 2nd Annual Capture Your Share of the Vaccine Market. Washington, D.C. June.
- 1999 A Worldwide approach to HIV Vaccine Development. 1998 Meeting of the Institute of Human Virology. Baltimore, M. D. August.

- 1999 HIV-1 DNA Vaccines for Thailand: Center For Vaccine Development. Bangkok, Thailand. August.
- 1999 Vaccine for HIV-1: Seaside Immunology Conference. October.
- 1999 Engineering Multicomponent HIV Vaccines, IRCM, Clinical Research Institute of Montreal, Montreal, Quebec. October.
- 1999 Advance in Plasmid vaccine technology, application to HIV-1. WHO International Meeting on DNA Vaccines, Langen Germany. October.
- 1999 Development and Clinical Progress of DNA Vaccines, Langen, Germany. Paul-Ehrlich-Institut October.
- 1999 Regulating Immune Response to a Multicomponent DNA Vaccine. A Century of Immunobiological Innovation. Berne, Switzerland. November
- 1999 Genes as Vaccines: An a Approach for Control of HIV-1. 1999 Genes as Vaccines: An a Approach for Control of HIV-1. 1999 USF Roy H. Behnke Distinguished Lecture. Tampa, Florida. February.
- 1999 Genes as Vaccines: An a Approach for Control of HIV-1. 1999 USF Roy H. Behnke Distinguished Lecture. 1999 Palm Springs Symposium, HIV Pathogenesis as a Foundation for New Therapies. Palm Springs, CA. March.
- 2000 Comparison of Effects of Cytokines upon Cellular and Humoral Immune Responses. Keystone Symposia, DNA Vaccines: Immune Responses, Mechanisms , and Manipulating Processing. Snowbird, Utah. April.
- 2000 Immune responses in primate to a DNA vaccine cocktail. 1st International Conference on Vaccine Development and Immunotherapy in HIV. Palm Beach, FL. June
- 2000 Engineering of DNA Vaccines for Human Immunodeficiency Virus (Plenary). World Congress on Vaccines and Immunization (2nd). Liege, Belgium. Aug - Sept
- 2000 Protection from disease progression and CD4 T-cell loss following mucosal challenge in macaques by plasmid vaccination. 2000 International Meeting of the Institute of Human Virology. Baltimore, MD. September.
- 2000 DNA vaccines in the 21st century. (plenary lecture) Japanese Society for Infes. Diseases, Haikkaido, November
- 2000 Advancements In Vaccines for HIV-1. (plenary lecture) Sapura Medical Center. Japan. November.
- 2000 Lesson learned from DNA technology, application to tuberculosis. Tuberculosis Vaccine 2000 Conference. Brown University, Providence, RI. November
- 2000 DNA vaccine Advances In HIV DNA Cassettes for Developing Nations-WRAIR-
- 2000 Engineering DNA Vaccines for HIV-1. Jefferson Center Biomedical Research Seminar. Thomas Jefferson University, Philadelphia, PA. December.
- 2001 DNA Vaccines and Molecular Adjuvants, NIBSC/MRC, England
- 2001 DNA Immunization as a Discovery Tool and Prophylactic Strategy for HIV-1. Special Guest Seminar, USF. Tampa, FL. March
- 2001 HIV-1vpr interferes with plasmid vaccine effectiveness in vivo, Keystone Symposia on HIV Pathogenesis & Vaccines, April, Colorado
- 2001 Second Generation DNA Vaccines - IAVI-Special Emphasis meeting DNA Vaccines, April, NYC
- 2001 DNA Vaccination as an immune therapeutic Approach for HIV-1, IHV Immune therapy meeting, April, Baltimore
- 2001 Designing a Vaccine for HIV-1, Nobel Symposia on DNA vaccines, Stockholm, June
- 2001 Advances in DNA Vaccine Technology, Plenary Lecturer, ESACT Meeting, Holmstadt, Sweden, June
- 2001 Are we Making Progress with DNA vaccines?, University of Pennsylvania, Department of Medicine, Allery and Immunology Seminar Series, June
- 2001 Gene Based Approaches for Human Disease, Wharton Seminars in Biotechnology, July, Philadelphia
- 2001 IL-15 enhances potency of a DNA vaccine for HIV-1, Baltimore Committee Vaccine Meeting, Philadelphia, September

- 2001 Building a better Molecular Adjuvants for HIV-1 Vaccines, IHV Annual Meeting, Baltimore
- 2001 Advancements in DNA Vaccine Technology, (Plenary Speaker) MPIER Immunology of the Eye Meeting, Oklahoma, October
- 2001 Clinical Implementation of DNA vaccines for HIV-1, VTN working group meeting, October, Seattle
- 2001 Where are we with DNA Vaccines for HIV-1, (Plenary Speaker) Pediatric IDSA Annual meeting, October, California
- immune therapy, IHGT Seminar Series, U. Pennsylvania, Philadelphia, November
- 2001 HIV-1 vpr suppresses immune responses in non human primates-Annual Meeting of Primate immunology and Vaccinology, Puerto Rico, November.
- 2002 Building the Next Generation of DNA Vaccines for HIV-1, Vaccine Research Center Seminar Series, National Institute of Health, Bethesda.
- 2002 Bioethics and Bioterrorism Conference, Presented by the Center for Bioethics at the University of Pennsylvania and the Center for Biomedical Ethics at the University of Virginia. Washington, DC, February
- 2002HIV Therapies: Bench to Bedside, Palm Springs, CA. March
- 2002 Engineering Potent HIV-1 DNA vaccines, Keystone DNA Vaccines Meetings. Keystone, Colorado. April
- 2002Vaccines for HIV-1 from Bench to Bedside, FASEB Mtg., New Orleans, LA. April
- 2002HIV DNA Vaccines at the Crossroads, Clinical Virology Meeting, Clearwater, Florida. May.
- 2002Improving HIV-1 DNA Vaccines for Immunotherapy-Immune mechanisms in HIV disease. Cleveland, OH, May.
- 2002 Engineering Potent Safe DNA Vaccines - Pathology Grand Rounds, Thomas Jefferson Medical School. Philadelphia, PA. May.
- 2002 Pushing the envelope of DNA vaccine technology, Third World congress on Vaccines and Immunisation. Opatja, Adriatic Riviera, Croatia. (Conference Co Chairman) June.
- 2002 DNA vaccination in the context of Immune Therapy- ACTG Washington, DC, July
- 2002 Designing DNA vaccines for agents of Bioterrorism – AVIDEX, Toronto Canada, October
- 2002 HIV vaccine development, clinical implementation issues for the developing world – Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy -Philadelphia October
- 2002 Agents of Bioterrorism: What are the risks for our current vaccines and how do we approach them? National Defense and Human Research Protections Conference, Washington, DC October
- 2002 Where are we in the development of a DNA vaccines for HIV-1?, International DNA Vaccines Meeting, Edinburgh, UK October
- 2002 The Next Generation of DNA Vaccines, National Cancer Institute lecture series, December
- 2003 Not Your Mothers DNA Vaccines, Institute for Human Virology, University of Maryland lecture Series, January
- 2003DNA Vaccines for HIV immune therapy, Wistar Institute, January
- 2003 DNA Vaccines for HIV –1, What's next?, Johns Hopkins University, January
- 2003 What have we learned regarding the next generation of DNA vaccines for HIV-1, Karolinska Institute lecture series, Stockholm, February
- 2003 Engineering DNA vaccines for HIV-1 in the context of Immune therapy 10th annual conference on Retroviruses and opportunistic infections, invited speaker, Boston, February.
- 2003 Cytokine Adjuvants for DNA vaccines: A critical breakthrough in the technology- HIV Vaccine Development- Keystone Symposia Invited Speaker, Banff, March.
- 2003 Vaccines in 2003: U. of Pennsylvania CFAR Press Educational Meeting, Philadelphia, April.
- 2003 Engineering Apoptosis to drive DNA vaccine induced immunity in vivo, ASM Annual Meeting Invited Speaker, Washington, DC, May
- 2003 Targeting HIV treatment through engineered DNA vaccines in patients on ART, International Conference on Immune Reconstitution and Control of HIV, Stressa, Italy, June.

- 2003 Cytokine enhancement of DNA vaccines for HIV-1 immune therapy and prophylaxis, Henry M. Jackson Foundation, Invited Seminar, Maryland, June
- 2003 Where is the DNA vaccine field going for HIV-1 Vaccines? Critical Path Breakfast Forum Speaker Series, Philadelphia, PA, June
- 2003 Effects of cytokine adjuvants on Plasmid DNA vaccine potency, Knowledge Foundation Forum on HIV Vaccines, Boston MA, June
- 2003 Cytokine adjuvants enhance DNA priming in non human primates, Basic Research Library, NCI/NIH Bethesda, MD, June
- 2003 HIV Accessory genes in viral replication, PRI Group Meeting, Rariton NJ, July
- 2003 DNA Vaccines for HIV immune therapy, ACTG, Arlington, VA, August
- 2003 Improved potency DNA Vaccines, USAMRIID, Ft. Detrich, MD, September
- 2003 HIV-1 Vpr interacts with a novel GR related receptor to suppress host cell immune responses, Annual meeting of the Institute for Human Virology, Baltimore, MD
- 2003 Potent CD8 T cell immunity can be induced by engineered DNA vaccines in non human primates, Cell and Molecular Biology Graduate Student Retreat, Faculty Speaker, Philadelphia, PA, October
- 2003 Ramping up the immune response to DNA vaccines by defined molecular adjuvants, Immune Modulation Symposium, J and J Annual symposia, Malvern, PA, October
- 2003 New strategies for control of HIV replication and pathogenesis targeting the VPR gene product of HIV-1. NIH Clinical Center- Special Lecture- November
- 2003 Status of HIV DNA Vaccine Development – Brown University- December
- 2004 T helper independent DNA vaccines for HIV-1. 2nd NIH sponsored HIV Immune Therapy Workshop, Reston, VA, January
- 2004 Cytokine Adjuvanted DNA vaccines that drive strong cellular immunity in non human primates. Keystone Meeting on Rational Design of Vaccines and Immune Therapeutics, Keystone, CO January

Bibliography

Research Publications (Peer Reviewed)

1. Hyman, J., J. Beekman, D. B. Weiner, and S. Sadove. 1981. Beached whale responds to rest and treatment. *Norden News*. 56:32.
2. Weiner, D. B., S. R. Watson, G. F. Babcock, and S. J. Keller. 1986. Expression of human T cell surface antigens in interspecies hybridomas. *Cell. Immunol.* 100:197-209.
3. Kokai, Y., K. Dobashi, D. B. Weiner, J. N. Myers, P. C. Nowell, and M. I. Greene. 1988. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. *Proc National Academy of Science U S A.* 85:5389-5393.
4. Maguire, H. C., D. B. Weiner, E. Sibinga, and M. I. Greene. 1988. The neu gene in 4 human neuroblastoma cell lines. *Adv. Neuroblastoma Res.* 2:165-173.
5. Mathews, E. A., S. J. Keller, and D. B. Weiner. 1988. A method to collect and culture skin biopsies from free ranging gray whales (*Eschrichtus robustus*). *Marine Mammol.* 4:196-202.
6. Weiner, D. B., K. Girard, W. V. Williams, T. McPhillips, and D. H. Rubin. 1988. Reovirus type 1 and type 3 differ in their binding to isolated intestinal epithelial cells. *Microb Pathog.* 5:29-40.
7. Weiner, D. B., J. Liu, N. Hanna, J. A. Bluestone, J. E. Coligan, W. V. Williams, and M. I. Greene. 1988. CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibitory cells. *Proc Natl Acad Sci U S A.* 85:6077-6081.
8. Weiner, D. B., R. M. Siegel, W. V. Williams, and M. I. Greene. 1988. Lymphocytes suppressive network and soluble effector mechanism. *Clin. Immunol.* 9:184-188.
9. Weiner, D. B., W. V. Williams, R. M. Siegel, S. Jerrold-Jones, and M. I. Greene. 1988. Molecular characterization of suppressor T cells : biology of transfusion induced immunosuppression. *Transplant Proc.* 20:1151-1153.

10. Williams, W. V., H. R. Guy, J. A. Cohen, D. B. Weiner, and M. I. Greene. 1988. Molecular and immunologic analyses of a functional internal image formed by an anti-receptor antibody. *Ann Inst Pasteur Immunol.* 139:659-675.
11. Williams, W. V., H. R. Guy, D. H. Rubin, F. Robey, J. N. Myers, T. Kieber-Emmons, D. B. Weiner, and M. I. Greene. 1988. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. *Proc Natl Acad Sci U S A.* 85:6488-6492.
12. Williams, W. V., D. A. Moss, D. B. Weiner, J. A. Cohen, H. R. Guy, and M. I. Greene. 1988. Anti-idiotypic modeled peptides with biologic activity. *Adv. Immunopharmacol.* 4:119-126.
13. Williams, W. V., D. B. Weiner, S. Wadsworth, and M. I. Greene. 1988. The antigen-major histocompatibility complex-T cell receptor interaction. A structural analysis. *Immunol Res.* 7:339-350.
14. Cohen, J. A., D. B. Weiner, K. F. More, Y. Kokai, W. V. Williams, H. C. Maguire, Jr., V. A. LiVolsi, and M. I. Greene. 1989. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. *Oncogene.* 4:81-88.
15. Cohen, J. A., W. V. Williams, D. B. Weiner, and M. I. Greene. 1989. Molecular aspects of ligand interaction with somatic and immune receptors: insights from studies of the mammalian reoviruses. *Chem Immunol.* 46:126-156.
16. Dobashi, K., D. B. Weiner, and M. I. Greene. 1989. Differential regulation of oncogenic and cellular p185 by serine/threonine kinases. *DNA.* 8:723-732.
17. Lavie, G., F. Valentine, B. Levin, Y. Mazur, G. Gallo, D. Lavie, D. Weiner, and D. Meruelo. 1989. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. *Proc Natl Acad Sci U S A.* 86:5963-5967.
18. Maguire, H. C., Jr., C. Jaworsky, J. A. Cohen, M. Hellman, D. B. Weiner, and M. I. Greene. 1989. Distribution of neu (c-erbB-2) protein in human skin. *J Invest Dermatol.* 92:786-790.
19. Romano, C., W. V. Williams, D. J. Fischberg, N. Cocero, D. B. Weiner, M. I. Greene, and P. B. Molinoff. 1989. Subtype-selective immunoprecipitation of the beta 2-adrenergic receptor. *J Neurochem.* 53:362-369.
20. Weiner, D. B., Y. Kokai, T. Wada, J. A. Cohen, W. V. Williams, and M. I. Greene. 1989. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. *Oncogene.* 4:1175-1183.
21. Weiner, D. B., J. Liu, J. A. Cohen, W. V. Williams, and M. I. Greene. 1989. The neu oncogene: A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. *Nature.* 339:230-231.
22. Williams, W. V., H. R. Guy, D. B. Weiner, and M. I. Greene. 1989. Three dimensional structure of a functional internal image. *Viral Immunol.* 2:239-246.
23. Williams, W. V., S. D. London, D. B. Weiner, S. Wadsworth, J. A. Berzofsky, F. Robey, D. H. Rubin, and M. I. Greene. 1989. Immune response to a molecularly defined internal image idiotope. *J Immunol.* 142:4392-4400.
24. Williams, W. V., D. A. Moss, T. Kieber-Emmons, J. A. Cohen, J. N. Myers, D. B. Weiner, and M. I. Greene. 1989. Development of biologically active peptides based on antibody structure [published erratum appears in *Proc Natl Acad Sci U S A* 1989 Oct;86(20):8044]. *Proc Natl Acad Sci U S A.* 86:5537-5541.
25. Williams, W. V., D. B. Weiner, and M. I. Greene. 1989. Development and use of antireceptor antibodies to study interaction of mammalian reovirus type 3 with its cell surface receptor. *Methods Enzymol.* 178:321-341.
26. Williams, W. V., D. B. Weiner, and M. I. Greene. 1989. Molecular analysis of primary T cell involvement in the idiotypic network utilizing immunoglobulin-derived peptides. *Year Immunol.* 6:152-161.
27. Williams, W. V., D. B. Weiner, D. H. Rubin, and M. I. Greene. 1989. Shared antigenic structure defines the neutralizing epitope of the reovirus type 3+. *Therapeutic Advances in Clinical Immunology: Immunology and Allergy Clinics of North America.* 8:169-172.
28. Barnathan, E. S., A. Kuo, K. Kariiko, L. Rosenfeld, S. Murray, N. Behrendt, E. Ronne, D. B. Weiner, J. Henkin, and D. B. Cines. 1990. Characterization of human endothelial cell receptor protein and mRNA for urokinase-type plasminogen activator. *Blood.* 76:1975-1806.

29. Cohen, J. A., W. V. Williams, D. B. Weiner, H. M. Geller, and M. I. Greene. 1990. Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes. *Proc Natl Acad Sci U S A.* 87:4922-4926.
30. Kelsten, M. L., M. S. Berger, H. C. Maguire, Jr., D. A. Chianese, M. E. Hellman, D. B. Weiner, and M. I. Greene. 1990. Analysis of c-erbB-2 protein expression in conjunction with DNA content using multiparameter flow cytometry. *Cytometry.* 11:522-532.
31. Kern, J. A., D. A. Schwartz, J. E. Nordberg, D. B. Weiner, M. I. Greene, L. Torney, and R. A. Robinson. 1990. p185neu expression in human lung adenocarcinomas predicts shortened survival. *Cancer Res.* 50:5184-5187.
32. Lodato, R. F., H. C. Maguire, Jr., M. I. Greene, D. B. Weiner, and V. A. LiVolsi. 1990. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. *Mod Pathol.* 3:449-554.
33. Weiner, D. B., K. Hubner, W. V. Williams, and M. I. Greene. 1990. Species tropism of HIV-1 infectivity of interspecific cell hybridomas implies non-CD4 structures are required for cell entry. *Cancer Detect Prev.* 14:317-320.
34. Weiner, D. B., D. E. McCallus, W. V. Williams, and M. I. Greene. 1990. Utilization of anti-idiotypic antibodies as molecular probes of virus receptor interaction. *Ann Inst Pasteur Immunol.* 140:92-106.
35. Weiner, D. B., J. Nordberg, R. Robinson, P. C. Nowell, A. Gazdar, M. I. Greene, W. V. Williams, J. A. Cohen, and J. A. Kern. 1990. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. *Cancer Res.* 50:421-425.
36. Williams, W. V., H. R. Guy, J. A. Cohen, D. B. Weiner, and M. I. Greene. 1990. Structure and regulation of internal image idiotypes. *Chem Immunol.* 48:185-208.
37. Williams, W. V., T. Kieber-Emmons, D. B. Weiner, and M. I. Greene. 1990. Use of antibodies as molecular mimics to probe intermolecular interaction landscapes. *SFI Studies in the Sciences of Complexity.* 9:1-10.
38. Williams, W. V., D. B. Weiner, T. Kieber-Emmons, and M. I. Greene. 1990. Antibody geometry and form: three-dimensional relationships between anti-idiotypic antibodies and external antigens. *Trends Biotechnol.* 8:256-263.
39. Modiano, J. F., Y. Kokai, D. B. Weiner, M. J. Pykett, P. C. Nowell, and C. R. Lyttle. 1991. Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. *J Cell Biochem.* 45:196-206.
40. Osther, K., G. Kellermann, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1991. Protective humoral immune responses to the human immunodeficiency virus induced in immunized pigs: a possible source of therapeutic immunoglobulin preparations. *Hybridoma.* 10:673-683.
41. Weiner, D. B., K. Huebner, W. V. Williams, and M. I. Greene. 1991. Human genes other than CD4 facilitate HIV-1 infection of murine cells. *Pathobiology.* 59:361-371.
42. Williams, T. M., D. B. Weiner, M. I. Greene, and H. C. Maguire, Jr. 1991. Expression of c-erbB-2 in human pancreatic adenocarcinomas. *Pathobiology.* 59:46-52.
43. Williams, W. V., T. Kieber-Emmons, J. VonFeldt, M. I. Greene, and D. B. Weiner. 1991. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. *J Biol Chem.* 266:5182-5190.
44. Williams, W. V., T. Kieber-Emmons, D. B. Weiner, D. H. Rubin, and M. I. Greene. 1991. Contact residues and predicted structure of the reovirus type 3-receptor interaction. *J Biol Chem.* 266:9241-9250.
45. Williams, W. V., D. B. Weiner, M. A. Borofsky, D. H. Rubin, K. Yui, and M. I. Greene. 1991. Modulations of T cell responses with MHC-derived peptides. *Immun. Res.* 11:11-23.
46. Borofsky, M. A., R. B. Zurier, H. Rosenbaum, D. B. Weiner, and W. V. Williams. 1992. Effects of polyunsaturated fatty acids on interleukin-2-dependent T cell growth. *Immunol Res.* 11:154-164.
47. Chen, S., A. R. Chrusciel, H. Nakanishi, A. Raktabut, M. E. Johnson, A. Sato, D. Weiner, J. Hoxie, H. U. Saragovi, M. I. Greene, and M. Kahn. 1992. Design and synthesis of a CD4 beta-turn mimetic that inhibits HIV gp120 binding and infection of human lymphocytes. *Proc. Natl. Acad. Sci.* 89:5872-5876.

48. Goddard, D. H., S. L. Grossman, W. V. Williams, D. B. Weiner, J. L. Gross, K. Eidsvoog, and J. R. Dasch. 1992. Regulation of synovial cell growth. Coexpression of transforming growth factor beta and basic fibroblast growth factor by cultured synovial cells. *Arthritis Rheum.* 35:1296-1303.
49. Kern, J. A., R. A. Robinson, A. Gazdar, L. Torney, and D. B. Weiner. 1992. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. *Am J Respir Cell Mol Biol.* 6:359-363.
50. Kieber-Emmons, T., J. F. Krowka, J. Boyer, K. E. Ugen, W. V. Williams, W. J. Morrow, and D. B. Weiner. 1992. Immunological characteristics of the putative CD4-binding site of the HIV-1 envelope protein. *Pathobiology.* 60:187-194.
51. Kieber-Emmons, T., and D. B. Weiner. 1992. Structural perspectives of the CD4 antigen. *Annals of AIDS.* 2:65-89.
52. Laczko, I., M. Hollosi, L. Urge, K. E. Ugen, D. B. Weiner, H. H. Mantsch, J. Thurin, and L. Otvos, Jr. 1992. Synthesis and conformational studies of N-glycosylated analogues of the HIV-1 principal neutralizing determinant. *Biochemistry.* 31:4282-4288.
53. Lee, A. H., T. Ramanujam, P. Ware, P. H. Edelstein, J. J. Brooks, B. Freundlich, H. R. Schumacher, Jr., R. B. Zurier, D. B. Weiner, and W. V. Williams. 1992. Molecular diagnosis of *Ureaplasma urealyticum* septic arthritis in a patient with hypogammaglobulinemia. *Arthritis Rheum.* 35:443-448.
54. McCallus, D. E., K. E. Ugen, A. I. Sato, W. V. Williams, and D. B. Weiner. 1992. Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. *Viral Immunol.* 5:163-172.
55. Osther, K., A. Wiik, F. Black, P. Skinhoj, G. Kellermann, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1992. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyperimmune porcine immunoglobulin to HIV-1. *AIDS.* 6:1457-164.
56. Rubin, D. H., D. B. Weiner, C. Dworkin, M. I. Greene, G. G. Maul, and W. V. Williams. 1992. Receptor utilization by reovirus type 3: distinct binding sites on thymoma and fibroblast cell lines result in differential compartmentalization of virions. *Microb Pathog.* 12:351-365.
57. Ugen, K. E., J. J. Goedert, J. D. Boyer, Y. Refaeli, Frank, I., W. V. Williams, A. Willoughby, S. Landesman, A. Rubinstein, T. Kieber-Emmons, and D. B. Weiner. 1992. Vertical transmission of HIV infection: reactivity of maternal sera to HIV-1 gp120 and gp41 peptides. *J. Clin. Invest.* 59:1923-1930.
58. Ugen, K. E., D. E. McCallus, J. M. Von Feldt, W. V. Williams, M. I. Greene, and D. B. Weiner. 1992. Ocular tissue involvement in HIV infection: immunological and pathological aspects. *Immunol Res.* 11:141-153.
59. Von Feldt, J. M., T. Kieber-Emmons, D. B. Weiner, K. E. Ugen, and W. V. Williams. 1992. Molecular structure and granulocyte/macrophage colony-stimulating factor activity. *DNA Cell Biol.* 11:183-191.
60. Wang, B., Q. Fang, W. V. Williams, and D. B. Weiner. 1992. Double-stranded DNA sequencing by linear amplification with Taq DNA polymerase. *Biotechniques.* 13:527-530.
61. Weiner, D. B. 1992. Insights into HIV infection and pathogenesis. *Pathobiology.* 60:177-180.
62. Weiner, D. B., W. V. Williams, P. B. Weisz, and M. I. Greene. 1992. Synthetic cyclodextrin derivatives inhibit HIV infection in vitro. *Pathobiology.* 60:206-212.
63. Weisz, P. B., H. C. Hermann, M. M. Joulle, K. Kumor, E. M. Levine, E. J. Macarak, and D. B. Weiner. 1992. Angiogenesis and heparin mimics. *Exs.* 61:107-117.
64. Williams, W. V., P. Callegari, B. Freundlich, G. Keenan, D. Eldridge, H. Shin, M. Kreitman, D. McCallus, and D. B. Weiner. 1992. Molecular diagnosis of *Borrelia burgdorferi* infection (Lyme disease). *DNA Cell Biol.* 3:207-214.
65. Williams, W. V., Q. Fang, D. Demarco, J. VonFeldt, R. B. Zurier, and D. B. Weiner. 1992. Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. *J Clin Invest.* 90:326-333.
66. Williams, W. V., D. E. McCallus, and D. B. Weiner. 1992.
67. Recombinant single chains human antibodies to HIV-1 gp160. *Transgene.* 1:1-20.
68. Williams, W. V., H. Rosenbaum, and D. B. Weiner. 1992. Effect of RNA concentration on cDNA synthesis for DNA amplification. *PCR Methods Appl.* 2:86-88.

69. Williams, W. V., A. Sato, M. Rossman, Q. Fang, and D. B. Weiner. 1992. Semi-random DNA amplification utilizing the polymerase chain reaction-application to the analysis of antigen receptor variable regions. *DNA and Cell Biology*. 11:707-720.
70. Williams, W. V., A. Sato, M. Rossman, Q. Fang, and D. B. Weiner. 1992. Specific DNA amplification utilizing the polymerase chain reaction and random oligonucleotide primers: application to the analysis of antigen receptor variable regions. *DNA Cell Biol*. 11:707-720.
71. Williams, W. V., J. M. VonFeldt, T. Ramanujam, and D. B. Weiner. 1992. Tyrosine kinase signal transduction in rheumatoid synovitis. *Semin Arthritis Rheum*. 21:317-329.
72. Williams, W. V., D. B. Weiner, M. A. Borofsky, D. H. Rubin, K. Yui, and M. I. Greene. 1992. Modulation of T cell responses with MHC-derived peptides. *Immunol Res*. 11:11-23.
73. Athreya, B. H., J. Pletcher, F. Zulian, D. B. Weiner, and W. V. Williams. 1993. Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro [published erratum appears in *Clin Immunol Immunopathol* 1993 Jul;68(1):93]. *Clin Immunol Immunopathol*. 66:201-211.
74. Bhat, S., R. V. Mettus, E. P. Reddy, K. E. Ugen, V. Srikantan, W. V. Williams, and D. B. Weiner. 1993. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. *AIDS Res Hum Retroviruses*. 9:175-181.
75. Kern, J. A., L. Torney, D. Weiner, A. Gazdar, H. M. Shepard, and B. Fendly. 1993. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. *Am J Respir Cell Mol Biol*. 9:448-454.
76. Levy, D. N., L. S. Fernandes, W. V. Williams, and D. B. Weiner. 1993. Induction of cell differentiation by human immunodeficiency virus 1 vpr. *Cell*. 72:541-550.
77. Ugen, K. E., J. J. Goedert, and D. B. Weiner. 1993. Maternal antibodies against HIV-1 envelope glycoprotein : model to evaluate vertical transmission / potential vaccine efficacy. *Arch. STD/HIV Res*. 7:223-228.
78. Wang, B., M. G. Agadjanyan, V. Srikantan, K. E. Ugen, W. Hall, M. H. Kaplan, K. Dang, W. V. Williams, and D. B. Weiner. 1993. Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion. *AIDS Res Hum Retroviruses*. 9:849-860.
79. Wang, B., J. Boyer, V. Srikantan, L. Coney, R. Carrano, C. Phan, M. Merva, K. Dang, L. Gilbert, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1993. DNA inoculation induces neutralizing immune responses against HIV-1 in mice and non human primates. *DNA and Cell Biology*. 12:799-804.
80. Wang, B., K. E. Ugen, V. Srikantan, M. G. Agadjanyan, K. Dang, Y. Refaeli, A. I. Sato, J. Boyer, W. V. Williams, and D. B. Weiner. 1993. Gene inoculation generates immune responses against human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A*. 90:4156-4160.
81. Williams, W. V., J. D. Boyer, M. Merva, V. Livolsi, D. Wilson, B. Wang, and D. B. Weiner. 1993. Genetic infection induces protective in vivo immune responses. *DNA Cell Biol*. 12:675-683.
82. Williams, W. V., T. Kieber-Emmons, Q. Fang, J. Von Feldt, B. Wang, T. Ramanujam, and D. B. Weiner. 1993. Conserved motifs in rheumatoid arthritis synovial tissue T-cell receptor beta chains. *DNA Cell Biol*. 12:425-434.
83. Agadjanyan, M. G., K. E. Ugen, B. Wang, W. V. Williams, and D. B. Weiner. 1994. Identification of an 80-kilodalton membrane glycoprotein important for human T-cell leukemia virus type I and type II syncytium formation and infection. *J Virol*. 68:485-493.
84. Agadjanyan, M. G., B. Wang, K. E. Ugen, T. Villafana, M. Merva, I. Petrushina, W. V. Williams, and D. B. Weiner. 1994. DNA inoculation with an HTLV-I envelope DNA construct elicits immune responses in rabbits, p. 47-53. *Vaccines '94 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
85. Athreya, B. A., F. Zulian, A. P. Godillot, D. B. Weiner, and W. V. Williams. 1994. Prolactin receptor levels on lymphocytes vary with menstrual cycle in women. *Pathobiology*. 62:34-42.
86. Coney, L., B. Wang, K. E. Ugen, D. E. McCallus, V. Srikantan, M. Agadjanyan, C. Patchuck, M. Merva, M. Newman, W. V. Williams, and D. B. Weiner. 1994. Facilitated DNA inoculation induces anti-HIV immunity in vivo. *Vaccine*. 12:1545-1550.

87. Eaton, A. M., K. E. Ugen, D. B. Weiner, T. Wildes, and J. A. Levy. 1994. An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. *AIDS Res Hum Retroviruses*. 10:13-18.
88. Kern, J. A., R. J. Slebos, B. Top, S. Rodenhuis, D. Lager, R. A. Robinson, D. Weiner, and D. A. Schwartz. 1994. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. *J Clin Invest*. 93:516-520.
89. Kieber-Emmons, T., J. M. von Feldt, A. P. Godillot, D. McCallus, V. Srikantan, D. B. Weiner, and W. V. Williams. 1994. Isolated VH4 heavy chain variable regions bind DNA characterization of a recombinant antibody heavy chain library derived from patient(s) with active SLE. *Lupus*. 3:379-392.
90. Levy, D. N., Y. Refaeli, R. R. MacGregor, and D. B. Weiner. 1994. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A*. 91:10873-10877.
91. Sato, A. I., F. B. Balamuth, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1994. Identification of CD7 glycoprotein as an accessory molecule in HIV-1-mediated syncytium formation and cellfree infection. *J Immunol*. 152:5142-5152.
92. Srikantan, V., B. Wang, M. A. Satre, K. E. Ugen, K. Dang, F. Scales, A. P. Godillot, W. V. Williams, and D. B. Weiner. 1994. Cloning and biological characterization of human single-chain Fv fragments that mediate neutralization of HIV-1. *AIDS*. 8:1525-1532.
93. Ugen, K. E., S. M. Galetta, J. M. VonFeldt, D. E. McCallus, W. V. Williams, and D. B. Weiner. 1994. Ocular manifestations of HIV-1 infection. *The AIDS Reader*. 4:66-71.
94. Ugen, K. E., V. Srikantan, B. Wang, J. Goedert, U. Ziegner, M. G. Agadjanyan, J. D. Boyer, J. P. Cotropia, W. V. Williams, and D. B. Weiner. 1994. Vertical transmission of human retroviral infections: immunological parameters. *Arch. STD/HIV Res*. 8:285-292.
95. Ugen, K. E., J. M. Von Feldt, D. B. Weiner, and U. Ziegner. 1994. Diagnosis and prediction of pediatric HIV-1 infection and AIDS : current status. *J. Clin. Lab. Anal*. 8:309-314.
96. Ugen, K. E., B. Wang, V. Ayyavoo, M. Agadjanyan, J. Boyer, F. Li, S. Kudchodkar, J. Lin, M. Merva, L. Fernandes, and et al. 1994. DNA inoculation as a novel vaccination method against human retroviruses with rheumatic disease associations. *Immunol Res*. 13:154-162.
97. Von Feldt, J. M., C. Monfardini, T. Kieber-Emmons, D. Voet, D. B. Weiner, and W. V. Williams. 1994. Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions. *Immunol Res*. 13:96-109.
98. Wang, B., M. Merva, K. Dang, K. E. Ugen, J. Boyer, W. V. Williams, and D. B. Weiner. 1994. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells. *AIDS Res Hum Retroviruses*. 10:S35-S41.
99. Williams, W. V., Q. Fang, J. M. Von Feldt, J. D. Boyer, M. Luchi, B. Wang, and D. B. Weiner. 1994. Immunotherapeutic strategies targeting rheumatoid synovial T-cell receptors by DNA inoculation. *Immunol Res*. 13:145-153.
100. Williams, W. V., J. M. VonFeldt, H. Rosenbaum, K. E. Ugen, and D. B. Weiner. 1994. Molecular cloning of a soluble form of the granulocyte-macrophage colony-stimulating factor receptor alpha chain from a myelomonocytic cell line. Expression, biologic activity, and preliminary analysis of transcript distribution. *Arthritis Rheum*. 37:1468-1478.
101. Williams, W. V., and D. B. Weiner. 1994. Introduction and Symposium Summary. *Immun. Res*. 13:77-81.
102. Zwillich, S. H., Q. Fang, T. Kieber-Emmons, J. Vonfeldt, D. Monos, T. Ramanujam, B. Wang, D. B. Weiner, and W. V. Williams. 1994. V alpha gene usage in rheumatoid compared with osteoarthritic synovial tissue T cells. *DNA Cell Biol*. 13:923-931.
103. Zwillich, S. H., D. B. Weiner, and W. V. Williams. 1994. T cell receptor analysis in rheumatoid arthritis: what have we learnt? *Immunol Res*. 13:29-41.
104. Boyer, J. D., B. Wang, K. E. Ugen, V. Srikantan, L. Gilbert, S. Kudchodkar, A. Javadian, K. Dang, M. Merva, M. Newman, R. Carrano, and D. B. Weiner. 1995. Induction of humoral and cellular immune response to HIV 1 in Cynomolgous macaques and chimpanzees, p. 99-104. *Vaccines '95 : Modern*

- Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
105. Levy, D. N., Y. Refaeli, and D. B. Weiner. 1995. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. *J Virol.* 69:1243-1252.
 106. Levy, D. N., Y. Refaeli, and D. B. Weiner. 1995. The vpr regulatory gene of HIV. *Curr Top Microbiol Immunol.* 193:209-236.
 107. Monfardini, C., T. Kieber-Emmons, J. M. VonFeldt, B. O'Malley, H. Rosenbaum, A. P. Godillot, K. Kaushansky, C. B. Brown, D. Voet, D. E. McCallus, and et al. 1995. Recombinant antibodies in bioactive peptide design. *J Biol Chem.* 270:6628-6638.
 108. Ramanujam, T., M. Luchi, H. R. Schumacher, S. Zwillich, C. P. Chang, P. E. Callegari, J. M. Von Feldt, Q. Fang, D. B. Weiner, and W. V. Williams. 1995. Detection of T cell receptors in early rheumatoid arthritis synovial tissue. *Pathobiology.* 63:100-108.
 109. Refaeli, Y., D. N. Levy, and D. B. Weiner. 1995. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. *Proc Natl Acad Sci U S A.* 92:3621-3625..
 110. VonFeldt, J. M., C. Monfardini, S. Fish, H. Rosenbaum, T. Kieber-Emmons, R. M. Williams, S. A. Khan, D. B. Weiner, and W. V. Williams. 1995. Development of GM-CSF antagonist peptides. *Peptide Research.* 8:20-32.
 111. Wang, B., J. Boyer, V. Srikantan, K. Ugen, M. Agadjanian, M. Merva, L. Gilbert, K. Dang, D. McCallus, K. Moelling, , R. Carrano, W.V. Williams, L. Coney and D.B. Weiner 1995. DNA inoculation induces cross clade anti-HIV-1 responses. *Ann N Y Acad Sci.* 772:186-197.
 112. Wang, B., J. Boyer, V. Srikantan, K. Ugen, L. Gilbert, C. Phan, K. Dang, M. Merva, M. G. Agadjanyan, M. Newman, , R. Carrano., D. McCallus, L. Coney, W.V. Williams, and D.B. Weiner. 1995. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. *Virology.* 211:102-112.
 113. Wang, B., J. D. Boyer, K. E. Ugen, V. Srikantan, V. Ayyaroo, M. G. Agadjanyan, W. V. Williams, M. Newman, L. Coney, R. Carrano, and Weiner, D. B. 1995. Nucleic acid-based immunization against HIV-1: induction of protective in vivo immune responses. *AIDS.* 9:S159-S170.
 114. Wang, B., M. Merva, K. Dang, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1995. Immunization by direct DNA inoculation induces rejection of tumor cell challenge. *Hum Gene Ther.* 6:407-418.
 115. Wang, B., M. Merva, W. V. Williams, and D. B. Weiner. 1995. Large-scale preparation of plasmid DNA by microwave lysis. *Biotechniques.* 18:554-555.
 116. Weiner, D. B. 1995. New vaccine strategies. *Mol Med Today.* 1:108-109.
 117. Williams, W. V., A. H. Rook, B. F. Freundlich, Q. Fang, E. Shaw, S. Lessin, and D. B. Weiner. 1995. T-cell receptors in scleroderma skin. The effect of photopheresis. *Ann N Y Acad Sci.* 756:424-427.
 118. Ayyavoo, V., K. E. Ugen, L. S. Fernandes, J. J. Goedert, A. Rubinstein, W. V. Williams, and D. B. Weiner. 1996. Analysis of genetic heterogeneity, antigenicity, and biological characteristics of HIV-1 in a maternal transmitter and nontransmitter patient pair. *DNA Cell Biol.* 15:571-580.
 119. Boyer, J. D., B. Wang, K. E. Ugen, M. Agadjanyan, A. Javadian, P. Frost, K. Dang, R. A. Carrano, R. Ciccarelli, L. Coney, W. V. Williams, and D. B. Weiner. 1996. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. *J Med Primatol.* 25:242-250.
 120. Cotropia, J., K. E. Ugen, S. Kliks, K. Broliden, P. A. Broliden, J. A. Hoxie, V. Srikantan, W. V. Williams, and D. B. Weiner. 1996. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. *J Acquir Immune Defic Syndr Hum Retrovirol.* 12:221-232.
 121. Li, F., R. Bulbul, H. R. Schumacher, Jr., T. Kieber-Emmons, P. E. Callegari, J. M. Von Feldt, D. Norden, B. Freundlich, B. Wang, V. Imonitie, C. P. Chang, I. Nachamkin, D. B. Weiner, and W. V. Williams. 1996. Molecular detection of bacterial DNA in venereal-associated arthritis [see comments]. *Arthritis Rheum.* 39:950-958.

122. Monfardini, C., T. Kieber-Emmons, D. Voet, A. P. Godillot, D. B. Weiner, and W. V. Williams. 1996. Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides. *J Biol Chem.* 271:2966-2971.
123. Monfardini, C., T. Kieber-Emmons, J. M. VonFeldt, A. P. Godillot, D. Voet, D. B. Weiner, and W. V. Williams. 1996. Rational design, analysis, and potential utility of GM-CSF antagonists. *Proc Assoc Am Physicians.* 108:420-431.
124. Monfardini, C., J. M. Von Feldt, T. Kieber-Emmons, H. Rosenbaum, A. P. Godillot, D. Voet, D. B. Weiner, and W. V. Williams. 1996. Recombinant antibody mimicry of granulocyte-macrophage colony stimulating factor : implications for cancer therapy. *Tumor Targeting.* 2:93-105.
125. Tokushige, K., T. Wakita, C. Pachuk, Moradpour, D. B. Weiner, V. R. Zurawski, Jr., and J. R. Wands. 1996. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. *Hepatology.* 24:14-20.
126. Agadjanyan, M., P. Luo, M. A. Westerink, L. A. Carey, W. Hutchins, Z. Steplewski, D. B. Weiner, and T. Kieber-Emmons. 1997. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. *Nature Biotechnol.* 15:547-551.
127. Agadjanyan, M. G., N. N. Trivedi, S. Kudchodkar, M. Bennett, W. Levine, A. Lin, J. Boyer, D. Levy, K. E. Ugen, J. J. Kim, and D. B. Weiner. 1997. An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV. *AIDS Res Hum Retroviruses.* 13:1561-1572.
128. Ayyavoo, V., S. Mahalingam, Y. Rafaeli, S. Kudchodkar, D. Chang, T. Nagashunmugam, W. V. Williams, and D. B. Weiner. 1997. HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoic cells in vitro. *J Leukoc Biol.* 62:93-99.
129. Ayyavoo, V., A. Mahboubi, S. Mahalingam, R. Ramalingam, S. Kudchodkar, W. V. Williams, D. R. Green, and D. B. Weiner. 1997. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B [see comments]. *Nature Medicine.* 3:1117-1123.
130. Ayyavoo, V., T. Nagashunmugam, J. Boyer, S. Mahalingam, L. S. Fernandes, P. Le, J. Lin, C. Nguyen, M. Chattergoon, J. J. Goedert, H. Friedman, and D. B. Weiner. 1997. Development of genetic vaccines for pathogenic genes: construction of attenuated vif DNA immunization cassettes. *AIDS.* 11:1433-1444.
131. Ayyavoo, V., Y. Rafaeli, T. Nagashunmugam, S. Mahalingam, M. T. Phung, A. Hamam, W. V. Williams, and D. B. Weiner. 1997. HIV-1 viral protein R (Vpr) as a regulator of the target cell. *Psychoneuroendocrinology.* 22:S41-S49.
132. Bagarazzi, M. L., J. D. Boyer, M. A. Javadian, M. Chattergoon, K. Dang, G. Kim, J. Shah, B. Wang, and D. B. Weiner. 1997. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. *J Medical Primatology.* 26:27-33.
133. Boyer, J. D., K. E. Ugen, M. Chattergoon, B. Wang, A. Shah, M. Agadjanyan, M. L. Bagarazzi, A. Javadian, R. Carrano, L. Coney, W. V. Williams, and D. B. Weiner. 1997. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. *J Infect Dis.* 176:1501-1509.
134. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination [see comments]. *Nature Medicine.* 3:526-532.
135. Chattergoon, M., J. Boyer, and D. B. Weiner. 1997. Genetic immunization: a new era in vaccines and immune therapeutics. *FASEB Journal.* 11:753-763.
136. Kim, J. J., V. Ayyavoo, M. L. Bagarazzi, M. Chattergoon, J. D. Boyer, B. Wang, and D. B. Weiner. 1997. Development of a multicomponent candidate vaccine for HIV-1. *Vaccine.* 15:879-883.
137. Kim, J. J., V. Ayyavoo, M. L. Bagarazzi, M. A. Chattergoon, K. Dang, B. Wang, J. D. Boyer, and D. B. Weiner. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. *J Immunol.* 158:816-826.
138. Kim, J. J., M. L. Bagarazzi, N. Trivedi, Y. Hu, K. Kazahaya, D. M. Wilson, R. Ciccarelli, M. A. Chattergoon, K. Dang, S. Mahalingam, A. A. Chalian, M. G. Agadjanyan, J. D. Boyer, B. Wang, and D. B.

- Weiner. 1997. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. *Nature Biotechnology*. 15:641-6.
139. Kim, J. J., and D. B. Weiner. 1997. DNA gene vaccination for HIV. *Springer Semin Immunopathol*. 19:175-194.
140. Mahalingam, S., V. Ayyavoo, M. Patel, T. Kieber-Emmons, and D. B. Weiner. 1997. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. *J Virol*. 71:6339-6347.
141. Mahalingam, S., B. MacDonald, K. E. Ugen, V. Ayyavoo, M. G. Agadjanyan, W. V. Williams, and D. B. Weiner. 1997. In vitro and in vivo tumor growth suppression by HIV-1 Vpr. *DNA Cell Biol*. 16:137-143.
142. Ugen, K. E., J. D. Boyer, B. Wang, M. Bagarazzi, A. Javadian, P. Frost, M. M. Merva, M. G. Agadjanyan, S. Nyland, W. V. Williams, L. Coney, R. Ciccarelli, and D. B. Weiner. 1997. Nucleic acid immunization of chimpanzees a prophylactic / immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial. *Vaccine*. 15:927-930.
143. Ugen, K. E., V. Srikantan, J. J. Goedert, R. P. Nelson, Jr., W. V. Williams, and D. B. Weiner. 1997. Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. *J Infect Dis*. 175:63-69.
144. Wang, B., K. Dang, M. G. Agadjanyan, V. Srikantan, F. Li, K. E. Ugen, J. Boyer, M. Merva, W. V. Williams, and D. B. Weiner. 1997. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. *Vaccine*. 15:821-825.
145. Yusibov, V., A. Modelska, K. Steplewski, M. Agadjanyan, D. Weiner, D. C. Hooper, and H. Koprowski. 1997. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. *Proc Natl Acad Sci U S A*. 94:5784-788.
146. Zhang, X., M. Gaubin, L. Briant, V. Srikantan, R. Murali, U. Saragovi, D. Weiner, C. Devaux, M. Autiero, D. Piatier-Tonneau, and M. I. Greene. 1997. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes [see comments]. *Nat Biotechnol*. 15:150-154.
147. Agadjanyan, M. G., M. A. Chattergoon, I. Petrushina, M. Bennett, J. Kim, K. E. Ugen, T. Kieber-Emmons, and D. B. Weiner. 1998. Monoclonal antibodies define a cellular antigen involved in HTLV-1 infection. *Hybridoma*. 17:9-19.
148. Agadjanyan, M. G., B. Wang, S. B. Nyland, D. B. Weiner, and K. E. Ugen. 1998. DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1. *Curr Top Microbiol Immunol*. 226:175-192.
149. Ayyavoo, V., T. Nagashunmugam, M. T. Phung, C. Buckner, S. Kudckodkar, P. Le, P. J. Reddy, L. Santiago, M. Patel, L. Tea, and D. B. Weiner. 1998. Construction of attenuated HIV-1 accessory gene immunization cassettes. *Vaccine*. 16:1872-1879.
150. Bagarazzi, M. L., J. D. Boyer, V. Ayyavoo, and D. B. Weiner. 1998. Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1. *Curr Top Microbiol Immunol*. 226:107-143.
151. Bagarazzi, M. L., J. D. Boyer, K. E. Ugen, M. A. Javadian, M. Chattergoon, A. Shah, M. Bennett, R. Ciccarelli, R. Carrano, L. Coney, and D. B. Weiner. 1998. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees. *Vaccine*. 16:1836-1841.
152. Boyer, J., K. Ugen, B. Wang, M. Chattergoon, A. Tsai, M. Merva, and D. B. Weiner. 1998. Induction of a TH1 type cellular immune response to the human immunodeficiency type 1 virus by in vivo DNA inoculation. *Dev Biol Stand*. 92:169-174.
153. Boyer, J. D., M. Bennett, M. A. Chattergoon, K. E. Ugen, A. Shah, A. Cohen, M. L. Bagarazzi, T. J. Higgins, Y. Baine, R. B. Ciccarelli, R. S. Ginsberg, J. J. Kim, R. R. MacGregor, and D. B. Weiner. 1998. Enhancement of cellular immune response in patients seropositive for HIV-1 utilizing DNA vaccines. *Proceedings of the 12th World AIDS Conference*. 2:441-446.
154. Boyer, J. D., M. Chattergoon, A. Shah, R. Ginsberg, R. R. MacGregor, and D. B. Weiner. 1998. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. *Dev Biol Stand*. 95:147-153.

155. Chattergoon, M. A., T. M. Robinson, J. D. Boyer, and D. B. Weiner. 1998. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. *J Immunol.* 160:5707-5718.
156. Cohen, A. D., J. D. Boyer, and D. B. Weiner. 1998. Modulating the immune response to genetic immunization. *FASEB J.* 12:1611-1626.
157. Kim, J. J., H. C. Maguire, Jr., L. K. Nottingham, L. D. Morrison, A. Tsai, J. I. Sin, A. A. Chalian, and D. B. Weiner. 1998. Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype. *J Interferon Cytokine Res.* 18:537-547.
158. Kim, J. J., L. K. Nottingham, J. Oh, D. Lee, K. Wang, M. Choi, T. Dentchev, D. Wilson, D. M. Cunnig, A. A. Chalian, J. Boyer, J. I. Sin, and D. B. Weiner. 1998. Rational vaccine design through the use of molecular adjuvants. *Gene Therapy and Molecular Biology.* 3:157-165.
159. Kim, J. J., L. K. Nottingham, J. I. Sin, A. Tsai, L. Morrison, J. Oh, K. Dang, Y. Hu, K. Kazahaya, M. Bennett, T. Dentchev, D. M. Wilson, A. A. Chalian, J. D. Boyer, M. G. Agadjanyan, and D. B. Weiner. 1998. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. *J Clin Invest.* 102:1112-1124.
160. Kim, J. J., and D. B. Weiner. 1998. Optimization of DNA Vaccines Through the Use of Molecular Adjuvants, *DNA Vaccines : Methods and Protocols*, V. 1, 19-32.
161. Kim, J. J., L. K. Nottingham, D. M. Wilson, M. L. Bagarazzi, A. Tsai, L. D. Morrison, A. Javadian, A. A. Chalian, M. G. Agadjanyan, and D. B. Weiner. 1998. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. *Vaccine.* 16:1828-1835.
162. Kim, J. J., N. N. Trivedi, L. K. Nottingham, L. Morrison, A. Tsai, Y. Hu, S. Mahalingam, K. Dang, L. Ahn, N. K. Doyle, D. M. Wilson, M. A. Chattergoon, A. A. Chalian, J. D. Boyer, M. G. Agadjanyan, and D. B. Weiner. 1998. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. *Eur J Immunol.* 28:1089-1103.
163. Kim, J. J., N. N. Trivedi, D. M. Wilson, S. Mahalingam, L. Morrison, A. Tsai, M. A. Chattergoon, K. Dang, M. Patel, L. Ahn, J. D. Boyer, A. A. Chalian, H. Schoemaker, T. Kieber-Emmons, M. A. Agadjanyan, H. Shoemaker and D. B. Weiner 1998. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine, *Oncogene.* 17:3125-3135.
164. Koprowski, H., and D. B. Weiner. 1998. DNA vaccination/genetic vaccination. *Curr Top Microbiol Immunol.* 226: V-XIII.
165. MacGregor, R. R., J. D. Boyer, K. E. Ugen, K. E. Lacy, S. J. Gluckman, M. L. Bagarazzi, M. A. Chattergoon, Y. Baine, T. J. Higgins, R. B. Ciccarelli, L. R. Coney, R. S. Ginsberg, and D. B. Weiner. 1998. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. *J Infect Dis.* 178:92-100.
166. Mahalingam, S., V. Ayyavoo, M. Patel, T. Kieber-Emmons, G. D. Kao, R. J. Muschel, and D. B. Weiner. 1998. HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. *Proc Natl Acad Sci U S A.* 95:3419-3424. .
167. Sin, J. I., J. J. Kim, K. E. Ugen, R. B. Ciccarelli, T. J. Higgins, and D. B. Weiner. 1998. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. *Eur J Immunol.* 28:3530-3540.
168. Ugen, K.E., S.B. Nyland, J.D. Boyer, C. Vidal, L. Lera, Rasheid, M. Chattergoon, M. L. Bagarazzi, R. Ciccarelli, T. Higgins, Y. Baine, R. Ginsberg, R. R. Macgregor, and D. B. Weiner. 1998. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. *Vaccine.* 16:1818-1821.
169. Wang, B., A. P. Godillot, M. P. Madaio, D. B. Weiner, and W. V. Williams. 1998. Vaccination against pathogenic cells by DNA inoculation. *Curr Top Microbiol Immunol.* 226:21-35.
170. Agadjanyan, M. G., J. J. Kim, N. Trivedi, D. M. Wilson, B. Monzavi-Karbassi, L. D. Morrison, L. K. Nottingham, T. Dentchev, A. Tsai, K. Dang, A. A. Chalian, M. A. Maldonado, W. V. Williams, and D. B. Weiner. 1999. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. *J Immunol.* 162:3417-3427.

171. Bagarazzi, M. L., J. D. Boyer, M. A. Javadian, M. A. Chattergoon, A. R. Shah, A. D. Cohen, M. K. Bennett, R. B. Ciccarelli, K. E. Ugen, and D. B. Weiner. 1999. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees. *J Infect Dis.* 180:1351-1355.
172. Boyer, J. D., M. A. Chattergoon, K. E. Ugen, A. Shah, M. Bennett, A. Cohen, S. Nyland, K. E. Lacy, M. L. Bagarazzi, T. J. Higgins, Y. Baine, R. B. Ciccarelli, R. S. Ginsberg, R. R. MacGregor, and D. B. Weiner. 1999. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. *Clin Immunol.* 90:100-107.
173. Boyer, J. D., J. Kim, K. Ugen, A. D. Cohen, L. Ahn, K. Schumann, K. Lacy, M. L. Bagarazzi, A. Javadian, R. B. Ciccarelli, R. S. Ginsberg, R. R. MacGregor, and D. B. Weiner. 1999. HIV-1 DNA vaccines and chemokines. *Vaccine.* 17:S53-S64.
174. Kim, J. J., L. K. Nottingham, A. Tsai, D. J. Lee, H. C. Maguire, J. Oh, T. Dentchev, K. H. Manson, M. S. Wyand, M. G. Agadjanyan, K. E. Ugen, and D. B. Weiner. 1999. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. *J Med Primatol.* 28:214-223.
175. Kim, J. J., K. A. Simbiri, J. I. Sin, K. Dang, J. Oh, T. Dentchev, D. Lee, L. K. Nottingham, A. A. Chalian, D. McCallus, R. Ciccarelli, M. G. Agadjanyan, and D. B. Weiner. 1999. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. *J Interferon Cytokine Res.* 19:77-84.
176. Kim, J. J., A. Tsai, L. K. Nottingham, L. Morrison, D. M. Cunnig, J. Oh, D. J. Lee, K. Dang, T. Dentchev, A. A. Chalian, M. G. Agadjanyan, and D. B. Weiner. 1999. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. *J Clin Invest.* 103:869-877.
177. Sin, J. I. & D. B. Weiner. 1999. Protective immune correlates can segregate by vaccine type in a murine herpes model system. *International Immunol.* 11:1763-1773.
178. Sin, J. I., M. Bagarazzi, C. Pachuk, and D. B. Weiner. 1999. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model. *DNA Cell Biol.* 18:771-779.
179. Sin, J. I., J. J. Kim, R. L. Arnold, K. E. Shroff, D. McCallus, C. Pachuk, S. P. McElhiney, M. W. Wolf, S. J. Pompa-de Bruin, T. J. Higgins, R. B. Ciccarelli, and D. B. Weiner. 1999. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. *J Immunol.* 162:2912-2921.
180. Sin, J. I., J. J. Kim, J. D. Boyer, R. B. Ciccarelli, T. J. Higgins, and D. B. Weiner. 1999. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. *J Virology.* 73:501-509.
181. Weiner, D. B., and R. C. Kennedy. 1999. Genetic Vaccines. *Scientific American.* 281:50-57.
182. Ayyavoo, V., S. Kudchodkar, M. P. Ramanathan, P. Le, K. Muthumani, N. M. Megalai, T. Dentchev, L. Santiago-Barrios, C. Mrinalini, and D. B. Weiner. 2000. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes. *AIDS.* 14:1-9.
183. Boyer, J. D., A. D. Cohen, S. Vogt, K. Schumann, B. Nath, L. Ahn, K. Lacy, M. L. Bagarazzi, T. J. Higgins, Y. Baine, R. B. Ciccarelli, R. S. Ginsberg, R. R. MacGregor, and D. B. Weiner. 2000. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. *J Infect Dis.* 181:476-483.
184. Dickey, C., U. Ziegner, M. G. Agadjanyan, V. Srikantan, Y. Refaeli, A. Prabhu, A. Sato, W. V. Williams, D. B. Weiner, and K. E. Ugen. 2000. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization. *DNA Cell Biol.* 19:243-252.
185. Kim, J. J., J. S. Yang, T. Dentchev, K. Dang, and D. B. Weiner. 2000. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. *J Interferon Cytokine Res.* 20: 487-498.
186. Kim, J. J., J. S. Yang, D. J. Lee, D. M. Wilson, L. K. Nottingham, L. Morrison, A. Tsai, J. Oh, K. Dang, T. Dentchev, M. G. Agadjanyan, J. I. Sin, A. A. Chalian, and D. B. Weiner. 2000. Macrophage colony-

- stimulating factor can modulate immune responses and attract dendritic cells in vivo. *Hum Gene Ther.* 11:305-321.
187. Kim, J. J., J. S. Yang, L. Montaner, D. J. Lee, A. A. Chalian, and D. B. Weiner. 2000. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. *J Interferon Cytokine Res.* 20:311-319.
 188. Kim, J. J., J. S. Yang, T. C. VanCott, D. J. Lee, K. H. Manson, M. S. Wyand, J. D. Boyer, K. E. Ugen, and D. B. Weiner. 2000. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. *J Virol.* 74:3427-3429.
 189. Lee, D., K. Wang, L. K. Nottingham, J. Oh, D. B. Weiner, and J. Kim, J. 2000. Gene-based vaccine strategies against cancer. *Gene Therapy and Molecular Biology.* 3:149-155.
 190. MacGregor, R. R., J. D. Boyer, R. B. Ciccarelli, R. S. Ginsberg, and D. B. Weiner. 2000. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type 1 env/rev vaccine in HIV-infected recipients: follow-up data. *J Infect Dis.* 181:406.
 191. Muthumani, K., L. J. Montaner, V. Ayyavoo, and D. B. Weiner. 2000. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1 Vpr function in macrophages and T-cells. *DNA Cell Biol.* 19:179-188.
 192. Patchuk, C. J., D. E. McCallus, D. B. Weiner, and C. Satishchandran. 2000. DNA vaccines - challenges in delivery. *Current Opinion in Molecular Therapeutics.* 2: 25-30.
 193. Sin, J. I., J. Kim, M. Chattergoon, V. Ayyavoo, D. McCallus, K. Ugen, J. D. Boyer, and D. B. Weiner. 2000. Engineering of DNA vaccines using molecular adjuvant plasmids. *Dev. Biol. Stand.* 104: 187-198.
 194. Viveros, M., C. Dickey, J. P. Cotropia, G. Gevorkian, C. Larralde, K. Broliden, M. Levi, A. Burgess, C. Cao, D. B. Weiner, M. G. Agadjanyan, and K. E. Ugen. 2000. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. *Virology.* 270:135-145.
 195. Kieber-Emmons T., B. Monzavi-Karbassi, B. Wang, P. Luo, and D. B. Weiner. DNA Immunization with Minigenes of Carbohydrate Mimotopes Induce Functional Anti-Carbohydrate Antibody Response. *J. Immunol.* 165:623-627. 2000.
 196. Kim J.J., J.S. Yang, T. Dentchev, K. Dang, and D. B. Weiner. 2000. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. *J. Interferon Cytokine Res.* 20:487-498.
 197. Sin, J.I., J. Kim, K. Dang, D. Lee, C. Patchuk, C. Satishchandran, and D. B. Weiner. 2000. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular mediated protective immunity against herpes simplex virus-2 in vivo : involvement of CD4+ T cells in protection. *Cellular Immunol.* 203:19-28.
 198. Boyer, J.D., A.D. Cohen, K.E. Ugen, R.L. Edgeworth, M. Bennett, A. Shah, K. Schumann, B. Nath, A. Javadian, M.I. Bagarazzi, J. Kim, and D. B. Weiner. 2000. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. *AIDS* 14:1515-1522.
 199. Muthumani, K., S. Kudchodkar, E. Papasavvas, L.J. Montaner, D. B. Weiner, and V. Ayyavoo. 2000. HIV-1 Vpr regulates expression of beta chemokines in human primary lymphocytes and macrophages. *J. Leukocyte Biol.* 68:366-372.
 200. Kang, CU, Weiner DB, Boyer JD, Genetic Immunization and Treatment of Disease, Expert Opinion on Therapeutic Patents, 10:1345-1355, 2000.
 201. Sin, J.I., J. Kim, C. Patchuk, and D. B. Weiner. 2000. Interleukin 7 can enhance cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. *Clin. Diagn. Lab. Immunol.* 7:751-758.
 202. Chattergoon, M., J.J. Kim, J.S. Yang, T. M. Robinson, D.J. Lee, T. Dentchev, D.M. Wilson, V. Ayyavoo, and D. B. Weiner. 2000. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis. *Nature Biotechnol.* 18:974-979.
 203. Patchuk, C., R.C. Ciccarelli, M. Samuel, M. E. Bayer, R. Troutman, D. Zurawski, J.I. Schauer, T. J. Higgins, D. B. Weiner, D.M. Sosnoski, V. R. Zurawski, and C. Satishchandran. 2000. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine. *Biophys. Biochim. Acta.* 1468: 20-30.

204. Sin, J.I., J.J. Kim, C. Pachuk, C. Satishchandran, and D.B. Weiner. 2000. DNA vaccines encoding IL-8 and RANTES enhance antigen-specific Th1 type CD4+ T cell mediated protective immunity against herpes simplex virus-2 in vitro. *J Virol.* 74: 11173-11180.
205. Weiner, D. B. 2000. Plasmid interleukin 12. *AIDS.* 14:1759-1760.
206. Shedlock, D.J. and D.B. Weiner. 2000. DNA vaccination: antigen presentation and the induction of immunity. *J. Leuk. Biol.* 68: 793-806.
207. Sin, J.I. and D. B. Weiner. 2001. Improving DNA vaccines targeting viral infection. *Intervirol.* 43: 233-246
208. Kim, J.J., J.S. Yang, K.H. Manson, and D.B. Weiner. 2001. Modulation of antigen-specific immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN- γ , or IL-4 gene adjuvants. *J. Virology* 74: 7 pp. 3427-3429.
209. Ramanathan, M.P., Ayyavoo, V., D.B. Weiner. 2001. Choice of Expression Vector Alters the Localization of a Human Cellular Protein. *DNA and Cell Biology*, 20;2 pp. 101-105.
210. Kim, J.J., Yang, J.S., Dang, K., Manson, K.H. D.B. Weiner 2001. Engineering Enhancement of Immune Responses to DNA-based Vaccines in a Prostate Cancer Model in Rhesus Macaques through the Use of Cytokine Gene Adjuvants. *Clinical Cancer Research* 7: pp 882-889.
211. Kim, J.J., Yang, J.S., Nottingham, L.K., Tang, W., Dang, K., Manson, K., Wyand, M.S., Wilson, D. M., Weiner, D.B. Induction of Immune Responses and Safety Profiles in Rhesus Macaques Immunized with a DNA Vaccine Expressing Human Prostate Specific Antigen (PSA). 2001, *Oncogene*. 20, 4497-4506.
212. Sin, J.I., Kim, J.J., Zhang, D., Weiner, D.B. 2001. Modulation of Cellular Responses by Plasmid CD40L: CD40L Plasmid Vectors Enhance Antigen-Specific Helper T Cell Type 1 CD4+ T Cell-Mediated Protective Immunity Against Herpes Simplex Virus Type 2 in Vivo. *Human Gene Therapy*, 12, 1091-1102.
213. Kim, J., Yang, J.S., Nottingham, L.K., Lee, D.J., Kellely, H., Manson, M., Wyand, M., Boyer, J.D., Ugen, K.E., Weiner, D.B., 2001. Protection from Immunodeficiency Virus Challenges in Rhesus Macaques by Multicomponent DNA Immunization. *Virology* 285, 204-217.
214. Vanitharani, R. Mahalingam, S. Rafaei, Y. Singh, S. P. Srinivasan, A. Weiner, D. B. & V. Ayyavoo HIV-1 Vpr Transactivates LTR-Directed Expression through Sequences Present within -278 to -176 and Increases Virus Replication in Vitro. (2001) *Virology*, 289, 2, 334-342.
215. Fernando, K.P., Muthumani, K., Zhang, D., Kudchodkar, S., Weiner, D.B., 2001 HIV DNA Vaccination: Advances and Experiences. *Bundesgesundheitsbl-Gesundheitsforsch.*, Springer-Verlag, 44: 1076-1082
216. Yang, J.S. J. Joseph Kim, D. Hwang, A. y. Choo, K. Deng, H. Maguire, S. Kudchodkar, M. Ramamathan and David B. Weiner, 2001. Induction of potent Th1 - Type Immune responses from a novel DNA vaccine for West Nile Virus New York Isolate (WNV-NY1999) *J. Infectious Diseases*, 184 (7) 809-816. 2001
217. Muthumani K, Kudchodkar S, Zhang D, Bagarazzi ML, Kim JJ, Boyer JD, Ayyavoo V, Pavlakis GN, Weiner DB. Issues for improving multiplasmid DNA vaccines for HIV-1. *Vaccine* (2002) 6; 20(15):1999-2003.
218. Ayyavoo, V., Muthumani, K., Kudchodkar, S., Zhang, D., Ramanathan, P., Dayes, N. S., Kim, J.J., Sin, Jeong-Im, Montaner, L.J. Weiner, D.B., HIV-1 Viral Protein R. Compromises Cellular Immune Function in vivo. *International Immunology*. 14(1) 13-22. 2002
219. Boyer, J.D., Chattergoon, Muthmani, K., Kudchodkar, S., Kim, J., Bagarazzi, M., Pavlakis, G., Sekaly, R., Weiner, Next Generation DNA Vaccines for HIV-1. *J. of Liposome Research* 12(1) 137-142. 2002.
220. Muthumani K, Zhang D, Hwang DS, Kudchodkar S, Dayes NS, Malik AS, Yang JS, Chattergoon MC, Desai BM, Maguire Jr HC and David B. Weiner. Adenovirus encoding HIV-1 Vpr activates Caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. *Oncogene* (2002) 11;21(30):4613-25.
221. Baumeister M, Chattergoon MA and Weiner DB. Prospects for an HIV vaccine; conventional approaches and DNA Immunization. *Biotechnology and Genetic Engineering Reviews*. Vol 19, 187-203. 2002.

222. MacGregor, RR., Ginsberg, R., Ugen, KE., Baine, Y., Kang, C., Tu, XM., Higgins, T., Weiner, DB., Boyer, JD., T cell Responses Induced in Normal Volunteers Immunized with a DNA Based Vaccine Containing HIV-1 Env and Rev, AIDS, 16:2137-2143, 2002.
223. Muthumani, K., Bagarazzi M., Conway D., Hwang, DS, Ayyavoo, V.,Zhang D., Manson, K., Kim, J., Boyer, J., Weiner, D.B., Inclusion of vpr accessory gene in a plasmid vaccine cocktail markedly reduces nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J. Med Primatology 31, 1-7 2002.
224. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes NS, Green DR, Weiner DB. HIV-1 Vpr Induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. Journal of Biological Chemistry (2002). 227(40): 37820-37831.
225. Boyer, JD, Schumann, K., Nath, B., Curley, E., Manson, K., Kim, JJ, and Weiner, DB., IL-4 Enhances SIV Responses in Infected Macaques, Journal of Parasitology, 32: 543-50, 2002.
226. Chattergoon MA, Maguire HH Jr, Robinson TM, Serrano E, Boyer JD, Weiner DB. immunization primes unique DTH responses to HIV-1MN envelope epitopes as compared to recombinant protein vaccination. Hybridomics. 2002 Apr; 21(2):117-22.
227. Ramanathan, P, and D. B. Weiner, Carboxy terminus of hVIP/mov34 is critical for Vpr interaction and glucocorticoid mediated signaling. J. Biological Chemistry, v277: 47854-47860, 2002.
228. Muthumani K, Hwang DS, Dayes NS, Kim JJ and Weiner DB. The HIV-1 accessory gene Vpr can inhibit antigen specific immune function. DNA and Cell Biology (2002). 21(9): 689-695.
229. Monzavi-Karbassi,B., Shamloo,S., Kieber-Emmons,M., Jousheghany,F., Lou,P., Lin,K.Y., Cunto-Amesty,G., Weiner, D.B., Kieber-Emmons, T., Priming characteristics of peptide mimotopes of carbohydrate antigens. (2003) Vaccine 21, 753-760.
230. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R, Isreal Z, Montefiori DC, Ugen K, Miller N, Kim J, Boyer J and Weiner DB. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIVmac251 challenge in Rhesus Macaques. Vaccine (2003). 21:629-637.
231. Chattergoon M, Weiner D. Plasmid DNA: Is there a Toll on the way to apoptosis? J Gene Med. 2002 Jan-Feb;4 (1):25-6.
232. Yang JS, Ramanathan MP, Muthumani K, Sung-Ha Jin, Q.C.Yu, Andrew Y. Choo, Daniel S. Hwang, Mark D. Lee, Kesen Dang, Waixing Tang, J. Joseph. Kim and David B. Weiner. Induction of inflammation by West Nile virus capsid through the Caspase-9 apoptotic pathway. Emerging Infectious Diseases (2002). 8(12): 1379-1384.
233. Boyer, J.D., Kutzler, M.A., Chattergoon, M.A., Calarota, S.A., Pavlakis, G., Sekaly, R-P. MacGregor, R.R., & David Weiner, Engineering DNA vaccination as an approach to HIV immune Therapy. Clinical and Applied Immunology Reviews 3:183-197 (2003).
234. Muthumani K, Zhang D, Dayes NS, Hwang DS, Kudchodkar S, Desai BM, Boyer JD and David B. Weiner. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces both humoral and cell-mediated immune responses in vivo. Virology (2003). v314, 134-146.
235. Muthumani K, Choo AY, Hwang DS, Chattergoon MA, Dayes N, Zhang D, Duvvuri U and David B. Weiner. Mechanism of HIV-1 Viral protein R (Vpr) induced apoptosis. Biochem Biophys Res Commun (2003) May 9; 304 (3) :583-92.
236. Agadjanyan MG, Chattergoon MA, Holterman MJ, Monzavi-Karbassi B, Kim JJ, Dentchev T, Wilson D, Choo AY, Ayyavoo V, Kiyatkin A, Montaner LJ, Kieber-Emmons T, Sekaly RP and Weiner DB. Co-stimulatory Molecule Immune Enhancement in a Plasmid Vaccine Model is regulated in part through the Immunoglobulin Constant-like Domain of CD80/86. Journal of Immunology. (2003) 171: 4311-4319.
237. S. A. Calarota, M. Otero, K. Hermanstayne, M. Lewis, M. Rosati, B. K. Felber, G. N. Pavlakis, J. D. Boyer & D. B. Weiner. Use of interleukin 15 to enhance interferon-gamma production by antigen-specific stimulated lymphocytes from rhesus macaques J. Immunological Methods. (2003) 279, 55-67..
238. M. A. Chattergoon, J. P. Shames and D. B. Weiner. Engineering cross-presentation in vivo. Expert Opinion on Biological Therapy (2003) 3: 887-894.

239. Chattergoon, M.A., Saulino, V., Shames, J., Stein, J., Montaner, L.J., & David B. Weiner. Co-immunization with plasmid IL-12 generates a strong T-cell memory response. 2004. In press, *Vaccines*
240. David B. Weiner, Keeping the lock on smallpox, *Nature Medicine*, 9, 9, 1115-1116.
241. Sandra A. Calarota and David B. Weiner, Present status of human HIV vaccine development. *AIDS*, 2004 in press.
242. Kim, J.J., Choo, A.Y., & David B. Weiner. DNA Vaccines., *Gene Therapy*, in press 2003.
243. Muthumani, K., Dayes, N.N., Hwang, D.S., Wadsworth, S., Abeyasinghe, H.R., Siekierka, J., and David B. Weiner, Suppression of HIV-1 Viral Replication by a novel p38 inhibitor, *AIDS*, 2004 in press.
244. Giri, M., Ugen, K., and David B. Weiner, DNA Vaccines Against HIV-1: Review of the Past Decade. *Clinical Microbiology Reviews*. 2004 in press.
245. Otero, M., Calarota, S., Felber, B., Laddy, D., Pavlakis, G., Boyer, J.D., And David B. Weiner. Resiquimod is a modest DNA vaccine adjuvant for HIV-1 gag DNA immunization. *Vaccines* 2004 in press.

Additional Publications

1. Kokai, Y., T. Wada, J. N. Myers, V. I. Brown, K. Dobashi, J. Cohen, J. Hamuro, D. B. Weiner, and M. I. Greene. 1988. The role of the neu oncogene product in cell transformation and normal development. *Princess Takamatsu Symposia proceedings*. 19:45-57.
2. Williams, W. V., H. R. Guy, J. A. Cohen, D. B. Weiner, and M. I. Greene. 1988. Structure of the neutralizing epitope of the reovirus type 3 hemagglutinin, p. 25-28. *Vaccines '88 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
3. Weiner, D. B., W. V. Williams, J. A. Hoxie, J. A. Berzofsky, and M. I. Greene. 1989. Non-CD4 molecules on human cells important in HIV-1 cell interactions, p. 115-120. *Vaccines '88 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
4. Kieber-Emmons, T., A. Whalley, W. M. Williams, T. Ryskamp, W. J. W. Morrow, J. Krowka, W. V. Williams, I. Schmid, J. V. Girogi, M. J. Merva, and D. B. Weiner. 1990. Biological characteristics of an HIV-1 envelope-derived synthetic peptide, p. 321-326. *Vaccines '90 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
5. Weiner, D. B., W. V. Williams, J. A. Hoxie, J. A. Berzofsky, and M. I. Greene. 1990. HIV infectivity : analysis of virus envelope determinants and target cell requirements for infectivity by HIV-1, p. 339-345. *Vaccines '90 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
6. Kieber-Emmons, T., K. E. Ugen, M. J. Merva, A. Whalley, W. J. W. Morrow, W. V. Williams, P. Nara, and D. B. Weiner. 1991. Engineered peptides that mimic HIV-1 neutralizing envelope structures, p. 165-173. *Vaccines '91 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
7. Ugen, K. E., B. Perussia, M. Kamoun, M. J. Merva, W. V. Williams, P. Nara, T. Kieber-Emmons, and D. B. Weiner. 1991. Inhibition of HIV-1 cellular infection by immunologic reagents, p. 115-121. *Vaccines '91 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
8. Cotropia, J., K. E. Ugen, D. Lambert, K. Ljunggren-Broliden, S. Kliks, J. Hoxie, and D. B. Weiner. 1992. Characterization of human monoclonal antibodies (HuMab) to the HIV-1 transmembrane (TM) gp41 protein, p. 157-163. *Vaccines '92 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
9. Sato, A. I., K. E. Ugen, W. V. Williams, B. Perussia, and D. B. Weiner. 1992. Identification of two non-CD4 molecules important for HIV-1 mediated syncytium formation, p. 223-228. *Vaccines '92 : Modern*

- Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
10. Ugen, K. E., J. J. Goedert, J. Boyer, Y. Refaeli, I. Frank, W. V. Williams, A. Willoughby, S. Landesman, A. Rubinstein, T. Kieber-Emmons, J. Berzofsky, and D. B. Weiner. 1992. Vertical transmission of HIV infection: maternal humoral immune responses to gp120 and gp41 peptides, p. 183-189. *Vaccines '92 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 11. Levy, D. N., and D. B. Weiner. 1993. HIV regulatory gene function analysis in rhabdomyosarcoma cell line, p. 243-250. *Vaccines '93 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 12. Sato, A. I., F. B. Balamuth, K. E. Ugen, W. V. Williams, D. B. Weiner, and D. Lambert. 1993. Anti-CD7 antibodies block cell adhesion and inhibit HIV syncytium formation, p. 189-196. *Vaccines '93 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 13. Wang, B., K. E. Ugen, V. Srikantan, M. G. Agadjanyan, K. Dang, A. I. Sato, Y. Refaeli, J. Boyer, W. V. Williams, and D. B. Weiner. 1993. Gene immunization : a novel method for vaccine development against HIV, p. 143-150. *Vaccines '93 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 14. Wang, B., M. Merva, K. Dang, J. Boyer, K. E. Ugen, V. LiVoisi, D. Wilson, F. Li, H. R. Schumacher, W. V. Williams, and D. B. Weiner. 1994. A novel system to evaluate DNA inoculation techniques for induction of in vivo protection, p. 83-90. *Vaccines '94 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 15. Williams, W. V., B. Wang, and D. B. Weiner. 1994. Genetic vaccination and older adults. *Inst. on Aging Newsletter*. 4:5-6.
 16. Pachuk, C., D. E. McCallus, L. R. Coney, B. Wang, J. Boyer, D. B. Weiner, T. Wakita, K. Tokushige, D. Moradpour, and J. R. Wands. 1995. HCV-core DNA vaccine constructs induce an anti-HCV core immune response, p. 123-128. *Vaccines '95 : Modern Approaches to New Vaccines*, Cold Spring Harbor, New York.
 17. Ugen, K. E., M. G. Agadjanyan, B. Wang, S. Kudchodkar, M. Merva, J. D. Boyer, F. Li, W. V. Williams, and D. B. Weiner. 1995. Elicitation of immune responses in rodents after DNA inoculation with an HTLV-I envelope glycoprotein expressing construct : a model for vaccination efficacy, p. 129-134. *Vaccines '95 : Modern Approaches to New Vaccines Including Prevention of AIDS*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 18. Boyer, J., B. Wang, K. E. Ugen, V. Srikantan, L. Gilbert, S. Kudchodkar, A. Javadian, K. Dang, M. Merva, D. McCallus, R. Ciccarelli, R. A. Carrano, L. Coney, and D. B. Weiner. 1996. Induction of humoral and cellular immune responses to HIV-1 in chimpanzees by in vivo DNA inoculation, p. 51-54. *Vaccines '96 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 19. McCallus, D., L. Coney, B. Wang, J. Boyer, C. Pachuk, T. Higgins, R. Carrano, D. Sims, K. Ugen, D. B. Weiner, and R. Ciccarelli. 1996. Facilitated DNA injection elicits specific anti-HIV immune responses in preclinical animal models, p. 55-60. *Vaccines '96 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 20. Ugen, K., J. D. Boyer, M. G. Agadjanyan, B. Wang, A. Javadian, L. Coney, D. McCallus, W. V. Williams, R. Ciccarelli, R. Carrano, and D. B. Weiner. 1996. Site-specific humoral immune responses generated in chimpanzees after DNA inoculation with HIV-1 envelope expressing constructs, p. 61-65. *Vaccines '96 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
 21. Agadjanyan, M. G., N. N. Trivedi, J. Kim, W. Levine, S. Kudchodkar, J. Boyer, M. Bennett, K. E. Ugen, and D. B. Weiner. 1997. HIV-2 expression vector generates cross strain humoral and cellular anti-HIV-2 as

- well as anti-SIV immune responses, p. 131-135. *Vaccines '97 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
22. Boyer, J. D., K. Ugen, M. Chattergoon, A. Tsai, L. Coney, and D. B. Weiner. 1997. Induction of a cross reactive cellular immune response to HIV-1 by in vivo DNA inoculation, p. 137-140. *Vaccines '97 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
23. Chattergoon, M., J. Boyer, V. Ayyavoo, R. R. Ginsberg, R. R. MacGregor, and D. B. Weiner. 1997. The challenge of vaccine development for HIV-1 : evaluation of DNA vaccination as an anti-HIV immunotherapy in infected chimpanzees, p. 145-149. *Vaccines '97 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
24. Ugen, K. E., J. Boyer, B. Wang, S. Gluckman, W. V. Williams, S. Coney, R. Ciccarelli, R. Ginsberg, R. R. MacGregor, and D. B. Weiner. 1997. Facilitated nucleic acid vaccination of humans with an HIV-1 expressing DNA boosts immune responses against the envelope glycoprotein, p. 145-149. *Vaccines '97 : Molecular Approaches to the Control of Infectious Diseases*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
25. Reddy, P. J., S. Kudchodkar, D. B. Weiner, and V. Ayyavoo. 1998. HIV-1 Vpr modulates cell proliferation and induces apoptosis in primary cells. *Proceedings of the 12th World AIDS Conference*. 2:423-427
26. Ugen, K. E., G. D. Rushing, C. Vidal, J. Kim, A. Javadian, J. Boyer, and D. B. Weiner. 1998. Beta chemokine levels in non-human primates modulated in vivo by HIV-1 DNA vaccines. *Proceedings of the 12th World AIDS Conference*. 5:55-59.
27. Ayyavoo, V., S. Kudchodkar, and D. B. Weiner. 1998. HIV-1 Accessory Genes : Roles in Viral Pathogenesis. In J. J. Oppenheim and E. M. Shevach (ed.), *HIV : Progress and Future Challenges*.
28. Boyer, J. D., V. Ayyavoo, J. Kim, and D. B. Weiner. 1998. DNA Vaccination as a Vaccine/Immune Therapeutic Approach for HIV-1, *IBC Vaccines : New Advances in Technologies and Applications*.
29. Chattergoon, M., J. Boyer, V. Ayyavoo, R. Ginsberg, R. R. MacGregor, and D. B. Weiner. 1998. The Challenge of Vaccine Development for HIV-1 : Evaluation of DNA Immunization as an Immunotherapeutic and Vaccine Strategy for HIV, *IBC Vaccines : New Advances in Technologies and Applications*, vol. 4.
30. Kim, J. J., L. K. Nottingham, A. Tsai, L. D. Morrison, J. Oh, T. Dentchev, T. C. VanCott, K. H. Manson, K. E. Ugen, and D. B. Weiner. 1998. Modulation of protective immunity in macaques using molecular adjuvants. *Proceedings of the 12th World AIDS Conference*. 5:35-39.
31. Kim, J. J., L. K. Nottingham, A. Tsai, J. Oh, T. Dentchev, D. Cunningham, A. A. Chalian, and D. B. Weiner. 1998. Rational engineering of immune responses using molecular adjuvants. *Proceedings of the 12th World AIDS Conference*. 1:289-294.
32. Kim, J.J. & D. B. Weiner: DNA Vaccination 1999 In Templeton and Lasick Eds, *Gene Therapy Humana Press* Chapter 20 pg 245-297.
33. Kudchodkar, S., T. Nagashunmugam, D. B. Weiner, and V. Ayyavoo. 2000. Human Immunodeficiency Virus Type 1 Accessory Genes : Targets for Therapy, p. 239-257. In K. E. Ugen and M. Bendinelli and H. Friedman (ed.), *Human Retroviral Infections : Immunotherapeutic and Therapeutic Control*. Kluwer Academic/Plenum Publishers, New York, NY.
34. Shah, A. R., D. B. Weiner, and J. D. Boyer. 2000. Nucleic Acid Vaccination Against HIV-1, p. 191-210. In K. E. Ugen and M. Bendinelli and H. Friedman (ed.), *Human Retroviral Infections: Immunotherapeutic and Therapeutic Control*. Kluwer Academic/Plenum Publishers, New York, NY.
35. J.E. Kallman, H.C. Macguire, J.S. Yang, J. J. Kim and David Weiner, 2001, Prophylactic and Therapeutic DNA vaccines against Infectious Diseases. In *the Skin and Gene Therapy*. Springer Verlag, New York.
36. Choo, A., Kim, J.J. & D. B. Weiner: DNA Vaccination 2003 In Templeton and Lasick Eds, *Gene Therapy* 2nd edition, Humana Press. In Press.

Books

Williams, W. V., and D. B. Weiner (ed.). 1994. Development and Utilization of Biologically Active Peptides, vol. 1. Technomic Publishers, Inc., Lancaster, PA.

Weiner, D. B. and W. V. Williams (ed.). 1995. Chemical and Structural Approaches to Rational Drug Design. CRC Press Inc., Boca Raton, FL.

Weiner, D. B., and H. Koprowski (ed.). 1998. DNA Vaccination / Genetic Vaccination. Springer-Verlag, Berlin and Heidelberg, Germany.